

MODULATORS OF THE
GLUCOCORTICOID RECEPTOR AND METHOD

This application claims priority from U.S. Provisional Application 60/396,877 filed July 18, 2002 which is incorporated herein by reference.

5

The present invention relates to new non-steroidal compounds which are glucocorticoid receptor (GR) modulators (that is agonists and antagonists) and thus are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes and inflammatory or immune associated diseases,
10 and to a method for using such compounds to treat these and related diseases.

BACKGROUND OF THE INVENTION

The nuclear hormone receptor (NHR) family of transcription factors bind low molecular weight ligands and either stimulate or repress transcription (The Nuclear
15 Receptor Facts Book, V. Laudet and H. Gronemeyer, Academic Press, p345, 2002). NHRs stimulate transcription by binding to DNA and inducing transcription of specific genes. NHRs may also stimulate transcription by not binding to DNA itself, rather they may modulate the activity of other DNA binding proteins (Stocklin, E., et al., Nature (1996) 383:726-8). The process of stimulation of transcription is called
20 transactivation. NHRs repress transcription by interacting with other transcription factors or coactivators and inhibiting the ability of these other transcription factors or coactivators from inducing transcription of specific genes. This repression is called transrepression. (for a review see The Nuclear Receptor Factsbook, V. Laudet and H. Gronemeyer, Academic Press, p42, 2002).

25 The glucocorticoid receptor (GR) is a member of the nuclear hormone receptor family of transcription factors, and a member of the steroid hormone family of transcription factors. Affinity labeling of the glucocorticoid receptor protein allowed the production of antibodies against the receptor which facilitated cloning the human (Weinberger, et al. Science 228, p640-742, 1985, Weinberger, et al. Nature, 318,
30 p670-672, 1986) and rat (Miesfeld, R. Nature, 312, p779-781, 1985) glucocorticoid receptors.



Glucocorticoids which interact with GR have been used for over 50 years to treat inflammatory diseases. It has been clearly shown that glucocorticoids exert their anti-inflammatory activity via the inhibition by GR of the transcription factors NF-kappaB and AP-1. This inhibition is termed transrepression. It has been shown that

5 the primary mechanism for inhibition of these transcription factors by GR is via a direct physical interaction. This interaction alters the transcription factor complex and inhibits the ability of NF-kappaB and AP-1 to stimulate transcription (Jonat, C., et al. Cell, 62, p1189, 1990, Yang-Yen, H.F., et al. Cell 62, p1205, 1990, Diamond, M.I. et al. Science 249, p1266, 1990, Caldenhoven, E. et al., Mol. Endocrinol. 9, p401,

10 1995). Other mechanisms such as sequestration of co-activators by GR have also been proposed (Kamer Y, et al., Cell 85, p403, 1996, Chakravarti, D. et al., Nature 383, p99, 1996). NF-kappaB and AP-1 play key roles in the initiation and perpetuation of inflammatory and immunological disorders (Baldwin, AS, Journal of Clin. Investigation 107, p3, 2001, Firestein, G.S., and Manning, A.M. Arthritis and

15 Rheumatism, 42, p609, 1999, Peltz, G., Curr. Opin, in Biotech. 8, p467, 1997). NF-kappaB and AP-1 are involved in regulating the expression of a number of important inflammatory and immunomodulatory genes including: TNF-alpha, IL-1, IL-2, IL-5, adhesion molecules (such as E-selectin), chemokines (such as Eotaxin and Rantes), Cox-2, and others.

20 In addition to causing transrepression, the interaction of a glucocorticoid with GR can cause GR to induce transcription of certain genes. This induction of transcription is termed transactivation. Transactivation requires dimerization of GR and binding to a glucocorticoid response element (GRE).

Recent studies using a transgenic GR dimerization defective mouse which

25 cannot bind DNA have shown that the transactivation (DNA binding) activities of GR could be separated from the transrepressive (non-DNA binding) effect of GR. These studies also indicate that many of the side effects of glucocorticoid therapy are due to the ability of GR to induce transcription of various genes involved in metabolism, whereas, transrepression, which does not require DNA binding leads to

30 suppression of inflammation (Tuckermann, J. et al. Cell 93, p531, 1998; Reichardt, HM. EMBO J., 20, p7168, 2001).

The art is in need of modulators of NHRs. A modulator of an NHR may be useful in treating NHR-associated diseases, that is diseases associated with the expression products of genes whose transcription is stimulated or repressed by NHRs. For instance, the art is in need of modulators of NHRs that inhibit AP-1 and NFκB, as
5 such compounds would be useful in the treatment of inflammatory and immune diseases and disorders such as osteoarthritis, rheumatoid arthritis, multiple sclerosis, asthma, inflammatory bowel disease, transplant rejection and graft vs. host disease.

Particularly concerning GR, although glucocorticoids are potent anti-inflammatory agents, their systemic use is limited by side effects. A compound that
10 retained the anti-inflammatory efficacy of glucocorticoids while minimizing the side effects such as diabetes, osteoporosis and glaucoma would be of great benefit to a very large number of patients with inflammatory diseases.


Additionally concerning GR, the art is in need of compounds that antagonize transactivation. Such compounds may be useful in treating metabolic diseases
15 associated with increased levels of glucocorticoid, such as diabetes, osteoporosis and glaucoma.

Additionally concerning GR, the art is in need of compounds that cause transactivation. Such compounds may be useful in treating metabolic diseases associated with a deficiency in glucocorticoid. Such diseases include Addison's
20 disease.

It is believed that the compounds of the present invention as described below fill the above needs.

DESCRIPTION OF THE INVENTION

25 In accordance with the present invention, compounds are provided having the structure



including all stereoisomers thereof, or a prodrug ester thereof, or a pharmaceutically acceptable salt thereof, wherein

R is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, arylalkyl, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, cyanoalkyl, aminoalkyl, hydroxyalkyl, aryloxyalkyl, or hydroxyaryl;

R^a is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cyano, halogen, heteroarylaminoalkyl, cycloheteroalkylcarbonyl, cyanoalkyl, alkylaminoalkyl, hydroxyalkyl, hydroxyaryl, aryloxyalkyl, nitro, amino, CHO, CO₂ alkyl, CONR^eR^f, CH₂NR^gR^h, CO₂H, CH₂OH, CH₂NHR^g, NHCH₂R^g, NHCHR^gR^h, NHCOR^e, NHCONR^eR^f or NHSO₂R^e;

R^b is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cyano, halogen, heteroarylaminoalkyl, cycloheteroalkylcarbonyl, cyanoalkyl, alkylaminoalkyl, hydroxyalkyl, nitro, amino, CHO, CO₂ alkyl, hydroxyaryl, aryloxyalkyl, CONRⁱR^j, CH₂NR^kR^l, CO₂H, CH₂OH, CH₂NHR^k, NHCH₂R^k, NHCHR^kR^l, NHCORⁱ, NHCONRⁱR^j or NHSO₂Rⁱ;

where R^e and R^f are the same or different and are independently selected from hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl, and R^e and R^f can be taken together with the nitrogen to which they are attached to form a 5-, 6- or 7-membered heteroaryl ring or cycloheteroalkyl ring which contains 1, 2 or 3 hetero atoms which can be N, O or S;

R^g and R^h are the same or different and are independently selected from hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl, and R^g and R^h can be taken together with the nitrogen to which they are attached to form a 5-, 6- or 7-membered heteroaryl ring or cycloheteroalkyl ring which contains 1, 2 or 3 hetero atoms which can be N, O or S;

R^i and R^j are the same or different and are independently selected from hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl, and R^i and R^j can be taken
 5 together with the nitrogen to which they are attached to form a 5-, 6- or 7-membered heteroaryl ring or cycloheteroalkyl ring which contains 1, 2 or 3 hetero atoms which can be N, O or S;

R^k and R^l are the same or different and are independently selected from hydrogen, aryl, alkyl, alkenyl, alkynyl, alkoxy, amino, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, cycloalkyl, or cycloalkylalkyl, and R^k and R^l can be taken
 10 together with the nitrogen to which they are attached to form a 5-, 6- or 7-membered heteroaryl ring or cycloheteroalkyl ring which contains 1, 2 or 3 hetero atoms which can be N, O or S;

15 R^c and R^d are the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, hydroxy, aryloxy, heteroaryl, cycloheteroalkyl, heteroarylalkyl, cycloheteroalkylalkyl, hydroxyaryl, or aryloxyalkyl;

R^c and R^d can be taken together with the carbon to which they are attached to form a 3- to 7-membered ring which may include an O or N atom in the ring;

20 Z is CONR^1R^2 or $\text{CH}_2\text{NR}^1\text{R}^2$ wherein R^1 and R^2 are the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloalkenyl, mono- or di-alkylaminoalkyl, cycloheteroalkylalkyl, hydroxyaryl, aryloxyalkyl, alkoxyalkyl or hydroxyalkyl;


25 the A ring represents a saturated, partially saturated or unsaturated 6-membered carbocyclic or heterocyclic ring; and

the B ring represents a saturated, partially saturated or unsaturated 6-membered carbocyclic or heterocyclic ring;

with the following provisos;


30 I. provided that where Z is CONR^1R^2 and (a) R is CH_3 or H and R^a , R^b , R^c and R^d are each hydrogen, or (b) R^a and R^b are each hydrogen and one of R^c and R^d is alkyl, then

(1) at least one of R^1 and R^2 is heteroaryl, heteroarylalkyl, cycloheteroalkyl or cycloheteroalkylalkyl, but where the heteroaryl is



5

or the heteroarylalkyl is



10 then the other of R^1 and R^2 is other than hydrogen, and/or the A ring and/or the B ring includes a hetero atom; or


(2) where one of R^1 and R^2 is phenyl which is substituted with alkyl, hydroxy, halo, C_1 - C_2 -alkoxycarbonyl or nitro, then (a) the phenyl must be substituted with at least one other group other than hydrogen, alkyl, hydroxy, halo, C_1 - C_2 -alkoxycarbonyl or nitro, except that the phenyl may be substituted with two or more halo atoms, and/or two or more hydroxy groups, and/or (b) the other of R^1 and R^2 is other than hydrogen and/or (c) the A ring and/or the B ring includes a hetero atom;

(3) where one of R^1 and R^2 is phenyl substituted with C_1 - C_2 alkoxy, the phenyl cannot be substituted with a second C_1 - C_2 alkoxy or the other of R^1 and R^2 is other than hydrogen, or


(4) where at least one of R^1 and R^2 is hydrogen, unsubstituted alkyl, alkenyl, cycloalkyl, alkylcycloalkyl, cycloalkenyl, alkylcycloalkenyl, alkylphenyl, monoalkylaminoalkyl, dialkylaminoalkyl, arylalkyl, aryl, alkoxyalkyl or hydroxyalkyl then (a) the other of R^1 and R^2 is other than hydrogen, unsubstituted alkyl, alkenyl, cycloalkyl, alkylcycloalkyl, cycloalkenyl, alkylcycloalkenyl, alkylphenyl, monoalkylaminoalkyl, dialkylaminoalkyl, arylalkyl, aryl, alkoxyalkyl or hydroxyalkyl; and/or (b) at least one of R^a , R^b , R^c and/or R^d is other than hydrogen and/or (c) R is other than hydrogen or C_1 - C_2 alkyl and/or (d) the A ring and/or the B ring includes a hetero atom; and

II. provided that where Z is $\text{CH}_2\text{NR}^1\text{R}^2$ and/or where at least one of R^1 and R^2 is hydrogen, alkyl, alkenyl, cycloalkyl, alkylcycloalkyl, phenyl, alkylphenyl, phenylalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, arylalkyl, aryl, alkoxyalkyl, hydroxyalkyl, heteroaryl which is pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl or imidazolyl, or cycloheteroalkyl which is 4,5-dihydro-imidazol-2-yl, piperidinyl or piperazinyl, then (a) the other of R^1 and R^2 is other than hydrogen, alkyl, alkenyl, cycloalkyl, alkylcycloalkyl, phenyl, alkylphenyl, phenylalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, arylalkyl, aryl, alkoxyalkyl or hydroxyalkyl and/or (b) at least one of R^a , R^b , R^c and/or R^d is other than hydrogen or C_{1-2} alkyl and/or (c) R is other than hydrogen or $\text{C}_1\text{-C}_2$ alkyl and/or (d) the A ring and/or the B ring includes a hetero atom and/or (e) one of R^c or R^d cannot be hydroxyalkyl.

In the compounds of formula I the A ring has the structure




and the B ring has the structure



wherein X_1 , X_2 , X_3 and X_4 are the same or different and are independently selected from CH, CH_2 , CHR^{15} , CR^{16} , $\text{CR}^{16}\text{R}^{17}$, N, NH, NR^{18} , O or S, and X_5 , X_6 , X_7 and X_8 are the same or different and are independently selected from CH, CH_2 , CHR^{19} , CR^{20} , $\text{CR}^{20}\text{R}^{21}$, N, NH, NR^{22} , O or S, wherein R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} and R^{22} are the same or different and are independently selected from hydrogen, alkyl, aryl, cycloalkyl, heteroaryl, and cycloheteroalkyl, wherein each of said A ring and said B ring contains at most two nitrogen ring atoms, at most two oxygen ring atoms and at most one sulfur ring atom.

It is preferred that the A ring and B ring are each 6-membered rings which are aromatic carbocyclic rings, namely benzo rings, or are heterocyclic rings each of which includes one hetero atom, which is nitrogen, namely pyridyl rings preferably


5



Preferred compounds of formula I of the invention which have glucocorticoid receptor (GR)/Dexamethasone (Dex) inhibition activity (>95% at 10 μ M) are set out below:

1. compounds of formula I of the invention where A and B are fused phenyl rings, R is CH_3 , R^a , R^b , R^c and R^d are each H, and Z is CONR^1R^2 where one of R^1 and R^2 is H and the other is heteroaryl, preferably imidazol-2-yl, that is

15



2. compounds of formula I of the invention where A and B are fused phenyl rings, R is CH_3 , R^a , R^b , R^c and R^d are each H, and Z is CONR^1R^2 where one of R^1 and R^2 is H and the other is heteroaryl, other than benzothiazol-2-yl, and preferably heteroaryl is alkylbenzothiazol-2-yl, alkoxybenzothiazol-2-yl, and halobenzothiazol-2-yl, such as


6-methylbenzothiazol-2-yl

4-methoxybenzothiazol-2-yl

6-fluorobenzothiazol-2-yl


6-chlorobenzothiazol-2-yl

for example, compounds of the structure



5 where X is 6-CH₃, 4-CH₃O, 6-Cl or 6-F.

3. compounds of formula I of the invention where A and B are fused phenyl rings, R is CH₃, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is a thiazole which preferably is substituted with dialkyl, alkyl,




optionally substituted with halo, alkyl, nitro, hydroxy, alkoxy, dialkoxy, carboxy, alkylaminocarbonyl, arylaminocarbonyl, hydroxyalkylaminocarbonyl, cycloheteroalkylcarbonyl, alkoxyalkylaminocarbonyl, heteroarylaminocarbonyl), heteroarylthio or heteroaryl such as

- 15 4,5-dimethylthiazol-2-yl
5-chlorothiazol-2-yl
4-methylthiazol-2-yl
5-methylthiazol-2-yl
4-phenylthiazol-2-yl
20 4-(1-naphthyl)thiazol-2-yl
5-(1-naphthyl)thiazol-2-yl
4-[1-(4-fluoro)naphthyl]thiazol-2-yl
4-[1-(4-methyl)naphthyl]thiazol-2-yl
4-(3-nitrophenyl)thiazol-2-yl
25 4-[1-(6-hydroxy)naphthyl]thiazol-2-yl
4-[(1,2,4-triazol-5-yl)thio]methylthiazol-2-yl

- 4-(4-benzoic acid)thiazol-2-yl
- 4-[1-(4-bromo)naphthyl]thiazol-2-yl
- 4-[4-N-ethylbenzamide]thiazol-2-yl
- 4-[4-N-(2-methoxyphenyl)benzamide]thiazol-2-yl
- 5 4-[4-N-methy-N-(2-hydroxyethyl)benzamide]thiazol-2-yl
- 4-[4-N-(pyrrolidinyl)benzamide]thiazol-2-yl
- 4-[4-N-(morpholinyl)benzamide]thiazol-2-yl
- 4-[4-N-phenyl-N-methylbenzamide]thiazol-2-yl
- 4-[3-N-ethylbenzamide]thiazol-2-yl
- 10 4-[3-N-(2-methoxyphenyl)benzamide]thiazol-2-yl
- 4-[3-N-(2-methoxyethyl)benzamide]thiazol-2-yl
- 4-[3-N-methyl-N-2-hydroxyethyl)benzamide]thiazol-2-yl
- 4-[3-N-methyl-N-phenylbenzamide]thiazol-2-yl
- 4-[3-N-(4-acetyl piperaziny-1-yl)benzamide]thiazol-2-yl
- 15 4-[3-N-(3-methoxypropyl)benzamide]thiazol-2-yl
- 4-(6-carboxypyrid-2-yl)thiazol-2-yl
- 4-[3-N-(3-hydroxy-4-methoxyphenyl)benzamide]thiazol-2-yl
- 4-[3-N-(3-fluoro-4-methoxyphenyl)benzamide]thiazol-2-yl
- 4-[3-N-(2,3-dimethoxyphenyl)benzamide]thiazol-2-yl
- 20 4-[3-N-(3-dimethoxyphenyl)benzamide]thiazol-2-yl
- 4-[3-N-(5-trifluormethyl-1,3,4-thiadiazol-2-yl)benzamide]thiazol-2-yl
- 4-[3-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzamide]thiazol-2-yl
- 4-[3-N-(5-chlorobenzoxazol-2-yl)benzamide]thiazol-2-yl
- 4-[3-N-(3-benzonitrile)benzamide]thiazol-2-yl
- 25 4-[3-N-(4-methoxypyrid-3-yl)benzamide]thiazol-2-yl
- 4-[5-(1,4-benzodioxane)]thiazol-2-yl
- 4-[4-(1,3-benzodioxole)]thiazol-2-yl,

for example, compounds of the structure



X = 4,5-dimethyl, 5-chloro, 4-methyl, 5-methyl, 4-phenyl, 4-(1-naphthyl), 4-(2-naphthyl), 4-(4-fluoronaphth-1-yl), 4-(4-methylnaphth-1-yl), 4-(3-nitrophenyl), 4-(6-hydroxynaphth-1-yl), 4-[(1,2,4-triazol-5-yl)thio]methyl, 4-benzoic acid, 4-(4-bromonaphth-1-yl), 4-(N-ethyl)benzamide, 4-(N-2-methoxyphenyl)benzamide, 4-(N-deoxyspergualin methyl-N-2-hydroxyethyl)benzamide, 4-(N-(pyrrolidinyl)benzamide, 4-(N-morpholinyl)benzamide, 4-(N-phenyl-N-methyl)benzamide, 3-(N-ethyl)benzamide, 3-(N-2-methoxyphenyl)benzamide, 3-(N-2-methoxyethyl)benzamide, 3-(N-methyl-N-2-hydroxyethyl)benzamide, 3-(N-methyl-N-phenyl)benzamide, 3-(N-4-acetylpiperazinyl-1-yl)benzamide, 3-(N-3-methoxypropyl)benzamide, 2-(6-carboxy)pyridine, 3-(N-3-hydroxy-4-methoxyphenyl)benzamide, 3-(N-3-fluoro-4-methoxyphenyl)benzamide, 3-(N-2,3-dimethoxyphenyl)benzamide, 3-(N-3-dimethoxyphenyl)benzamide, 3-(N-5-trifluormethyl-1,3,4-thiadiazol-2-yl)benzamide, 3-(N-5-methyl-1,3,4-thiadiazol-2-yl)benzamide, 3-(N-5-chlorobenzoxazol-2-yl)benzamide, 3-(N-3-benzonitrile)benzamide, 3-(N-4-methoxypyrid-3-yl)benzamide, 5-(1,4-benzodioxane), 4-(1,3-benzodioxole).

4. compounds of formula I of the invention where A and B are fused phenyl rings, R is C₂H₅, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is heteroaryl, preferably thiazol-2-yl or 4-(1-naphthyl)thiazol-2-yl.

5. compounds of formula I of the invention where A and B are fused phenyl rings, R is 2-hydroxyethyl, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is heteroaryl, preferably thiazol-2-yl.


6. compounds of the formula I of the invention where A and B are fused phenyl rings, R is CH₃, R^a, R^b, R^c and R^d are H, and Z is CONR¹R² where one of R¹ and R² is H and the other is a heteroaryl, preferably 2-quinolin-1-yl.

5 Preferred compounds of formula I of the invention which have AP-1 inhibitory activity (IC₅₀ <15 μM) are set out below:

1(a). compounds of formula I of the invention where A and B are fused phenyl rings, R is CH₃, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is heteroaryl, preferably imidazole which is preferably substituted with an aryl group, which preferably is naphthyl preferably substituted with alkyl, halo or alkoxy, such as


- 4-(1-naphthyl)imidazol-2-yl
- 4-[1-(4-methyl)naphthyl]imidazol-2-yl
- 15 4-[1-(4-fluoro)naphthyl]imidazol-2-yl
- 4-[1-(6-methoxynaphthyl)]imidazol-2-yl
- 4-phenylimidazol-2-yl
- 4-t-butylimidazol-2-yl

20 for example, compounds of the structure



X is aryl or alkyl, such as 1-naphthyl, 1-[(4-methyl)naphthyl], 1-(4-fluoro)naphthyl, 1-(6-methoxynaphthyl), phenyl, t-butyl, or quinolinyl optionally substituted with alkyl such as methyl and/or alkoxy such as methoxy, or isoquinolinyl optionally substituted with alkyl such as methyl and/or alkoxy such as methoxy.

1(b). compounds of the structure




5	<u>R^a</u>	<u>R^b</u>	<u>X</u>
	H	H	
	H	nitro	
	H	H	
	H	nitro	
10	H	H	
	H	nitro	
	H	H	
	H	nitro	

15 2. compounds of formula I of the invention where A and B are fused phenyl rings, R is CH₃, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is heteroaryl, preferably an oxazole which is preferably substituted with an aryl group which preferably is naphthyl such as 4-(1-naphthyl)oxazol-2-yl,

20

that is, a compound of the structure




where X is aryl such as 1-naphthyl.

5

3. compounds of formula I of the invention where A and B are fused phenyl rings, R is CH₃, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is a pyridyl which is preferably substituted with an aryl group which preferably is naphthyl, such as 4-(1-naphthyl)pyrid-2-yl, that is a compound of

10 the structure



where X is aryl such as 1-naphthyl.

15

4. compounds of formula I of the invention where A and B are fused phenyl rings, R is CH₃, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is a heteroaryl, preferably a thiazole substituted with alkyl, aryl, heteroaryl or alkoxy, and where the aryl is phenyl, naphthyl or anthracenyl, which

20 preferably is substituted with halo, alkyl, alkoxy, aryl, or hydroxy, such as

4-(phenyl)thiazol-2-yl

4-(t-butyl)thiazol-2-yl


4-(1-naphthyl)thiazol-2-yl

4-[1-(4-fluoro)naphthyl]thiazol-2-yl

25 4-(benzthiophen-3-yl)thiazol-2-yl

- 4-[1-(4-methyl)naphthyl]thiazol-2-yl
- 4-[1-(2-methoxynaphthyl)]thiazol-2-yl
- 4-[1-(6-methoxynaphthyl)]thiazol-2-yl
- 4-(3-fluorophenyl)thiazol-2-yl
- 5 4-(4-fluorophenyl)thiazol-2-yl
- 4-(3-methylphenyl)thiazol-2-yl
- 4-(2-chlorophenyl)thiazol-2-yl
- 4-[1-(4-methoxynaphthyl)]thiazol-2-yl
- 4-[1-(4-bromonaphthyl)]thiazol-2-yl
- 10 4-[1-(4-iodonaphthyl)]thiazol-2-yl
- 4-[anthracen-5-yl)]thiazol-2-yl
- 4-[anthracen-1-yl)]thiazol-2-yl
- 4-[4-quinolin-1-yl)]thiazol-2-yl
- 4-[2-quinolin-1-yl)]thiazol-2-yl
- 15 4-[1-(4-cyano-naphthyl)]thiazol-2-yl
- 5-iodothiazol-2-yl
- 4-(benzthiophen-4-yl)thiazol-2-yl
- 4-[1-(2-hydroxynaphthyl)]thiazol-2-yl
- 4-[1-(6-hydroxynaphthyl)]thiazol-2-yl
- 20 4-[1-(4-hydroxynaphthyl)]thiazol-2-yl

for example, compounds of the structure



25


where X is aryl, alkyl, heteroaryl or halo, such as phenyl, t-butyl, 1-naphthyl, 1-(4-fluoro)naphthyl, benzthiophen-3-yl, 1-(4-methyl)naphthyl, 1-(2-methoxy)naphthyl, 1-(6-methoxy)naphthyl, 3-fluorophenyl, 4-fluorophenyl, 3-methylphenyl, 2-

chlorophenyl, 1-(4-methoxy)naphthyl, 1-(4-bromo)naphthyl, 1-(4-iodo)naphthyl, 5-anthracenyl, 1-anthracenyl, 4-quinolin-1-yl, 2-quinolin-1-yl, 1-(4-cyano)naphthyl, 5-iodo, 4-benzthiophenyl, 1-(2-hydroxy)naphthyl, 1-(6-hydroxy)naphthyl, 1-(4-hydroxy)naphthyl.

5


5. compounds of formula I of the invention where A and B are fused phenyl rings, R is C₂H₅, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is a heteroaryl, preferably thiazole which is substituted with aryl, preferably naphthyl, such as 4-(1-naphthyl)thiazol-2-yl, that is

10




6. compounds of formula I of the invention where A and B are fused phenyl rings, R is CH₃, R^a, R^b, R^c and R^d are each H, and Z is CONR¹R² where one of R¹ and R² is H and the other is

15



that is

20




- where X is aryl, alkoxyaryl, dialkoxyaryl, heteroaryl, heteroarylalkyl, halo (alkoxy)-aryl, hydroxy (alkoxy)aryl, trialkoxyaryl, alkyl(alkoxy)aryl, haloaryl, dihaloaryl,
 5 heteroarylaryl, alkylthioaryl, alkenylaryl, alkoxyheteroaryl, cyanoaryl, where aryl is phenyl or naphthyl and heteroaryl by itself or part of another group is pyridyl, imidazolyl, azido, isothiazolyl, pyrazolyl or thiadiazolyl;

preferred examples of X include

- 10 phenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,5-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3-pyridyl, 2-(4-pyridyl)ethyl, 2-(4-imidazolyl)ethyl, 3-chloro-4-methoxyphenyl, 3-hydroxy-4-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 4-methyl-3-methoxyphenyl, 3-methoxyphenyl, 3,5-dimethoxyphenyl, 2,3-dimethoxyphenyl, 4-chlorophenyl, 2-
 15 naphthyl, 3-chlorophenyl, 3,4-dichlorophenyl, 4-azidophenyl, 2,4-dimethoxyphenyl, 3-ethoxyphenyl, 3-(methylthio)phenyl, 4-(methylthio)phenyl, 3-(acetylenyl)phenyl, 4-methoxy-3-pyridyl, 3-cyanophenyl, 2-methyl-4-methoxyphenyl, 3-azidophenyl, 3-methyl-isothiazolyl, 1-methyl-pyrazol-5-yl or 5-trifluormethyl-1,3,4-thiadiazol-2-yl.


- 20 7. compounds of formula I of the invention of the structure

(a)




	<u>R^a</u>	<u>R^b</u>	<u>X</u>
5	carboxymethyl	H	H
	nitro	H	H
	cyano	H	H
	carboxymethyl	H	methyl
	nitro	H	methyl
	cyano	H	methyl
10	H	carboxymethyl	H
	H	nitro	H
	H	cyano	H
	H	formyl	H
	H	CO-(N-morpholine)	H
	H	CH ₂ -NH-ethyl	H
15	H	CH ₂ -(N-morpholine)	H
	H	nitro	methyl
	H	cyano	methyl
	H	NH ₂	methyl
	H	nitro	F
	H	cyano	F
20	H	Cl	H
	H	Cl	F
	H	Cl	Methyl
	H	Br	F
	H	Br	Methyl
	H	CH ₃	H
25	H	CH ₃	F
	H	CH ₃	Methyl

(b)



(c)

ii



5

Q = N, Y = CH or Q = CH, Y = N

Z = CONR¹R²


R = CH₃

10 R^a, R^b, R^c, R^d are H

R² = 4-(4-fluoronaphthyl)thiazol-2-yl

R¹ = H.

(d)




15

	<u>R^a</u>	<u>R^b</u>	<u>X</u>
	CH ₃ OOC -	H	H
	Nitro	H	H
	Cyano	H	H
5	CH ₃ OOC -	H	Methyl
	Nitro	H	Methyl
	Cyano	H	Methyl
	H	CH ₃ OOC -	H
	H	Nitro	H
10	H	Cyano	H
	H	formyl	H
	H	CO-(N-morpholine)	H
	H	- CH ₂ -NH-Ethyl	H
	H	- CH ₂ -(N-morpholine)	H
15	H	Nitro	Methyl
	H	Cyano	Methyl
	H	NH ₂	Methyl
	H	Nitro	F
	H	Cyano	F
20	H	Cl	H
	H	Cl	F
	H	Cl	Methyl
	H	Br	F
	H	Br	Methyl
25	H	CH ₃	H
	H	CH ₃	F
	H	CH ₃	Methyl

8. compounds of formula I of the structure


30

lj




wherein one of R^1 and R^2 is heteroaryl, preferably wherein one of R^1 and R^2 is

5




where R^m is selected from H, alkyl, aryl, heteroaryl, halo, or alkoxy and R^o is H or
10 alkyl, and more preferably where one of R^1 and R^2 is



Other preferred compounds of the invention have the structure

15



lk




where R is CH₃, C₂H₅ or 2-hydroxyethyl, R_b is H, CN, NO₂, halogen, alkyl or amino, and

- X_b is H, arylalkoxycarbonyl, arylalkylaminocarbonyl, alkoxyalkylaminocarbonyl, heteroarylcarbonyl, aryl, alkoxyalkylamidocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, arylaminocarbonylaryl or heteroaryl; provided that where X_b is H, then R is C₂H₅ or 2-hydroxymethyl or R_b is CN or NO₂.


Examples of the above preferred compounds include the following:




(Chiral (R))




(Chiral (S))




(Chiral (R))




(Chiral (S))



5






(Chiral (R))





(Chiral (S))


10





5




10






5



Still other preferred compounds of the invention have the structure





10




where R is CH₃, C₂H₅ or 2-hydroxyethyl, Rb is H, CN, NO₂, halogen, alkyl or amino, and Xc is aryl, quinolinyl or isoquinolinyl.

15




Examples of the above preferred compounds include the following:



5




10




5


(Chiral (S))







(Chiral (R))



10





5

10 In another aspect of the present invention, there is provided pharmaceutical compositions useful in treating endocrine disorders, rheumatic disorders, collagen diseases, dermatologic disease, allergic disease, ophthalmic disease, respiratory disease, hematologic disease, gastrointestinal disease, inflammatory disease, autoimmune disease, diabetes, obesity, and neoplastic disease, as well as other uses as

15 described herein, which includes a therapeutically effective amount (depending upon

use) of a compound of formula I of the invention and a pharmaceutically acceptable carrier.

In still another aspect, the present invention provides a method of preventing, inhibiting onset of or treating endocrine disorders, rheumatic disorders, collagen
5 diseases, dermatologic disease, allergic disease, ophthalmic disease, respiratory disease, hematologic disease, gastrointestinal disease, inflammatory disease, autoimmune disease, diabetes, obesity, and neoplastic disease, GR-associated diseases, that is a disease associated with the expression product of a gene whose transcription is stimulated or repressed by GR or a disease associated with GR
10 transactivation, including inflammatory and immune diseases and disorders as described hereinafter, which includes the step of administering a therapeutically effective amount of a compound of formula I of the invention to a patient in need of treatment.

Another aspect of the present involves a method for preventing, inhibiting
15 onset of or treating a disease associated with AP-1-dependent gene expression, that is a disease associated with the expression of a gene under the regulatory control of AP-1, such as inflammatory and immune disorders, cancer and tumor disorders, such as solid tumors, lymphomas and leukemia, and fungal infections such as mycosis fungoides.

20 The term "disease associated with GR transactivation," as used herein, refers to a disease associated with the transcription product of a gene whose transcription is transactivated by a GR. Such diseases include, but are not limited to: osteoporosis, diabetes, glaucoma, muscle loss, facial swelling, personality changes, hypertension, obesity, depression, and AIDS, the condition of wound healing, primary or secondary
25 adrenocortical insufficiency, and Addison's disease.

The term "treat", "treating", or "treatment," in all grammatical forms, as used herein refers to the prevention, reduction, or amelioration, partial or complete alleviation, or cure of a disease, disorder, or condition.

The terms "glucocorticoid receptor" and "GR," as used herein, refer either to a
30 member of the nuclear hormone receptor family of transcription factors which bind glucocorticoids and either stimulate or repress transcription, or to GR-beta. These terms, as used herein, refer to glucocorticoid receptor from any source, including but

not limited to: human glucocorticoid receptor as disclosed in Weinberger, et al. Science 228, p640-742, 1985, and in Weinberger, et al. Nature, 318, p670-672, 1986; rat glucocorticoid receptor as disclosed in Miesfeld, R. Nature, 312, p779-781, 1985; mouse glucocorticoid receptor as disclosed in Danielson, M. et al. EMBO J., 5, 2513; 5 sheep glucocorticoid receptor as disclosed in Yang, K., et al. J. Mol. Endocrinol. 8, p173-180, 1992; marmoset glucocorticoid receptor as disclosed in Brandon, D.D., et al, J. Mol. Endocrinol. 7, p89-96, 1991; and human GR-beta as disclosed in Hollenberg, SM. et al. Nature, 318, p635, 1985, Bamberger, C.M. et al. J. Clin Invest. 95, p2435, 1995.

10 The term, "disease associated with AP-1-dependent gene expression," as used herein, refers to a disease associated with the expression product of a gene under the regulatory control of AP-1. Such diseases include, but are not limited to: inflammatory and immune diseases and disorders; cancer and tumor disorders, such as solid tumors, lymphomas and leukemia; and fungal infections such as mycosis 15 fungoides.

 The term "inflammatory or immune associated diseases or disorders" is used herein to encompass any condition, disease, or disorder that has an inflammatory or immune component, including, but not limited to, each of the following conditions: transplant rejection (e.g., kidney, liver, heart, lung, pancreas (e.g., islet cells), bone 20 marrow, cornea, small bowel, skin allografts, skin homografts (such as employed in burn treatment), heart valve xenografts, serum sickness, and graft vs. host disease, autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, Type I and Type II diabetes, juvenile diabetes, obesity, asthma, inflammatory bowel disease (such as Crohn's disease and ulcerative colitis), 25 pyoderma gangrenum, lupus (systemic lupus erythematosus), myasthenia gravis, psoriasis, dermatitis, dermatomyositis; eczema, seborrhoea, pulmonary inflammation, eye uveitis, hepatitis, Grave's disease, Hashimoto's thyroiditis, autoimmune thyroiditis, Behcet's or Sjorgen's syndrome (dry eyes/mouth), pernicious or immunohaemolytic anaemia, atherosclerosis, Addison's disease (autoimmune disease 30 of the adrenal glands), idiopathic adrenal insufficiency, autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), glomerulonephritis, scleroderma, morphea, lichen planus, viteligo (depigmentation of the skin), alopecia

areata, autoimmune alopecia, autoimmune hypopituitarism, Guillain-Barre syndrome, and alveolitis; T-cell mediated hypersensitivity diseases, including contact hypersensitivity, delayed-type hypersensitivity, contact dermatitis (including that due to poison ivy), urticaria, skin allergies, respiratory allergies (hayfever, allergic rhinitis) and gluten-sensitive enteropathy (Celiac disease); inflammatory diseases such as osteoarthritis, acute pancreatitis, chronic pancreatitis, acute respiratory distress syndrome, Sezary's syndrome and vascular diseases which have an inflammatory and or a proliferatory component such as restenosis, stenosis and atherosclerosis.

Inflammatory or immune associated diseases or disorders also includes, but is not limited to: endocrine disorders, rheumatic disorders, collagen diseases, dermatologic disease, allergic disease, ophthalmic disease, respiratory disease, hematologic disease, gastrointestinal disease, inflammatory disease, autoimmune disease, congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcemia associated with cancer, juvenile rheumatoid arthritis, Ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis, acute rheumatic carditis, pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme, exfoliative dermatitis, seborrheic dermatitis, seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions, allergic conjunctivitis, keratitis, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, optic neuritis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis chemotherapy, idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, leukemias and lymphomas in adults, acute leukemia of childhood, regional enteritis, autoimmune vasculitis, multiple sclerosis, chronic obstructive pulmonary disease, solid organ transplant rejection, sepsis.

In addition, in accordance with the present invention a method of treating a disease associated with AP-1-induced or NFκB-induced transcription is provided wherein a compound of formula I of the invention is administered to a patient in need of treatment in a therapeutically effective amount to induce NHR transrepression of the AP-1-induced or NFκB-induced transcription, thereby treating the disease.

Other therapeutic agents, such as those described hereafter, may be employed with the compounds of the invention in the present methods. In the methods of the present invention, such other therapeutic agent(s) may be administered prior to, simultaneously with or following the administration of the compound(s) of the present invention.

In a particular embodiment, the compounds of the present invention are useful for the treatment of the aforementioned exemplary disorders irrespective of their etiology, for example, for the treatment of transplant rejection, rheumatoid arthritis, inflammatory bowel disease, and viral infections.


METHODS OF PREPARATION

The compounds of the present invention may be synthesized by many methods available to those skilled in the art of organic chemistry. General synthetic schemes, in accordance with the present invention, for preparing compounds of the present invention are described below. These schemes are illustrative and are not meant to limit the possible techniques one skilled in the art may use to prepare the compounds disclosed herein. Different methods to prepare the compounds of the present invention will be evident to those skilled in the art. Additionally, the various steps in the synthesis may be performed in an alternate sequence in order to give the desired compound or compounds. Examples of compounds of the present invention prepared by methods described in the general schemes are given in the preparations and examples section set out hereinafter.


Compounds of formula 1

Compounds of formula I of the invention are prepared as described in the Schemes and examples below. In the schemes the various groups A, B, Z, R, R^a, R^b, R^c, and R^d correspond to those described above.

5

Scheme A

- General methods for the synthesis of compounds of the invention of structure
- 10 IA of the invention where A and B are each fused phenyl or pyridyl, and Z is
- $\begin{array}{c} \text{O} \\ || \\ \text{C-NR}^1\text{R}^2 \end{array}$ are well known in the literature. Compound IA is constructed by the
- cycloaddition of a compound of formula 1 with an unsaturated compound of formula
- 2 neat or in an appropriate solvent such as xylenes or benzene, at temperatures
- ranging from 50 to 200 °C to form compound 3 (which is a novel intermediate). It is
- 15 well known that the cycloaddition may be facilitated by the use of a catalysts such
- diethylaluminium chloride or boron trifluoride diethyl etherate. The cycloaddition
- may also be carried out at higher pressures as when the reactions are performed in
- sealed vessels.



Compound 3 is reacted with an amine of formula 4 by one of the many methods of amidation well known to those skilled in the art (preferably treatment of 3 in a suitable solvent such as acetonitrile with diethylaminoethyl chloride hydrochloride (DEC), 1-hydroxy-7-azabenzotriazole, triethylamine and amine 4) to provide compounds of the invention of structure IA.


The starting compound 1 is known in the art and may be commercially available or prepared employing procedures known in the art.

Scheme B

Compounds of formula I of the invention where R is other than H and Z is




(that is IA) may be prepared preferably starting with compound 3 where R is H which is treated with a suitable base such as lithium diisopropylamide (LDA) in a suitable solvent such as tetrahydrofuran or dethyl ether and at a temperature ranging from -100°C to 100°C and with a compound 5 ($\text{R}^x\text{-LG}$, where LG is a leaving group, such as methyl iodide and R^x is R other than H) affords compounds of structure 6. Compound 6 may be subjected to amidation as described in Scheme A to form compounds of the invention IA (where R is other than H).



Scheme C


- Compounds of formula I of the invention where Z is $\text{C}(=\text{O})\text{NR}^1\text{R}^2$ where each of
- 5 R^1 and R^2 is other than H may be prepared starting with compound of formula IA where R^{1a} is R^1 other than H and R^2 is H which is treated with base such as sodium hydride and compound $\underline{5a}$ $R^{2a}\text{-LG}$, where LG is a leaving group, such as methyl iodide, and R^{2a} is R^2 other than H, to provide compounds of structure IB of the invention where R^1 and R^2 are other than H.

10




Scheme D

Compounds of formula I of the invention where Z is $-\text{CH}_2\text{NR}^1\text{R}^2$ (that is IC) may be prepared starting with compounds of formula IA which when treated with a reducing agent such as lithium aluminum hydride (LAH) provides compounds IC of the invention.

Scheme E

Compounds of formula I of the invention where one or more of A, B, Z, R, R^a, R^b, R^c and R^d includes a hydroxyaryl group may be prepared as follows.

A compound of formula IA of the invention that contains one or more aryloxyalkyl groups located in A, B, Z, R, R^a, R^b, R^c, and R^d when treated with dealkylating agent such as boron tribromide, sodium methyl sulfide or other known dealkylating agents provides phenols of formula ID of the invention.




one or more of A, B, Z, R, R^a, R^b, R^c or R^d contains-aryl-Oalkyl

the corresponding A, B, Z, R, R^a, R^b, R^c or R^d contains-aryl-OH

Scheme F


A compound of formula IE where R^a or R^b is a functional group such as CHO, NH₂, CO₂H or NO₂ may be further elaborated by various methods well known to

those skilled in the art to give compounds of structure IF. A few illustrative examples are shown below. The newly introduced groups may also be further elaborated,



5


The following compounds are new intermediates and may be prepared employing procedures set out hereinbefore and/or known in the art:



10


or an alkyl ester thereof,

where R is CH₃, C₂H₅; R^a is nitro, cyano, Cl, Br, CH₃, -COOCH₃, formyl and R^b is H; R^b is nitro, cyano, Cl, Br, CH₃, -COOCH₃, formyl and R^a is H; and



15

where X₉ is S or NH; X is :




DEFINITION OF TERMS

- Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as
- 5 employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, and may optionally include an oxygen or nitrogen in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-
- 10 trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents such as halo, for example F, Br, Cl or I or CF₃, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl, heteroaryl, heteroaryloxy, HO-N=, cycloheteroalkyl,
- 15 alkyloxycarbonyl, alkoxyoximyl, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido, alkanoylamino, hydroxyalkyl (alkyl)amino carbonyl, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl and/or alkylthio and/or any of the substituents for aryl.

- Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or
- 20 as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocycloalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons

forming the rings, preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,


5



any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and/or alkylthio and/or any of the substituents for alkyl.

The term "cycloalkenyl" as employed herein alone or as part of another group refers to cyclic hydrocarbons containing 3 to 12 carbons, preferably 5 to 10 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.

The term "cycloalkylene" as employed herein refers to a "cycloalkyl" group which includes free bonds and thus is a linking group such as



and the like, and may optionally be substituted as defined above for "cycloalkyl".

The term "alkanoyl" as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.

Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, and may optionally include an oxygen or nitrogen in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-

heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, alkylthio and/or any of the substituents for alkyl set out herein.

Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, and may optionally include an oxygen or nitrogen in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or any of the substituents for alkyl set out herein.

The terms "arylalkenyl" and "arylalkynyl" as used alone or as part of another group refer to alkenyl and alkynyl groups as described above having an aryl substituent.

Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may optionally be substituted as defined above for "alkyl".




Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted as defined above for "alkenyl" and "alkynyl".

$(CH_2)_p$ and $(CH_2)_q$, includes alkylene, allenyl, alkenylene or alkynylene groups, as defined herein, each of which may optionally include an oxygen or nitrogen in the normal chain, which may optionally include 1, 2, or 3 substituents which include alkyl, alkenyl, halogen, cyano, hydroxy, alkoxy, amino, thioalkyl, keto, C_3-C_6



cycloalkyl, alkylcarbonylamino or alkylcarbonyloxy; the alkyl substituent may be an alkylene moiety of 1 to 4 carbons which may be attached to one or two carbons in the $(CH_2)_p$ or $(CH_2)_q$ group to form a cycloalkyl group therewith.

Examples of $(CH_2)_p$, $(CH_2)_q$, alkylene, alkenylene and alkynylene include




5




10




15



20






5


The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF₃, with chlorine or fluorine being preferred.

The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.

Unless otherwise indicated, the term "aryl" , as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings for example

20





- 5 and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxy carbonyl, aryl carbonyl, arylalkenyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, aryl or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxy carbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino or arylsulfonaminocarbonyl, carboxy, cycloalkyl, arylalkoxy, aryloxy carbonyl, cycloalkylaminocarbonyl, cycloalkylalkylaminocarbonyl, alkoxy carbonylalkyl, alkoxyalkylaminocarbonyl, heteroarylaminocarbonyl, heteroarylalkylaminocarbonyl, arylalkylaminocarbonyl, N-hydroxyalkyl(N-alkyl)aminocarbonyl, cycloheteroalkylaminocarbonyl, cycloheteroalkylalkylaminocarbonyl, N-aryl(N-alkyl)aminocarbonyl, N-arylalkyl(N-cyanoalkyl)aminocarbonyl, dialkylaminoalkylaminocarbonyl, dialkylaminocarbonyl, alkyl-, arylalkyl- or aryl-cycloheteroalkylaminocarbonyl, N-dialkylaminoalkyl(N-alkyl or N-arylalkyl)aminocarbonyl, N-heteroarylalkyl(N-alkyl)aminocarbonyl, N-arylalkyl(N-alkyl)aminocarbonyl, N-dialkylamino(N-arylalkyl)aminocarbonyl, N-hydroxyalkyl(N-
- 10
- 15
- 20
- 25

arylalkyl)aminocarbonyl, aminoalkyloxycarbonyl, cycloheteroalkylcarbonyl, N=N=N, alkylsulfonyl, aminosulfonyl, heteroarylaminosulfonyl, and/or any of the substituents for alkyl set out herein.

Unless otherwise indicated, the term "lower alkoxy", "alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.

Unless otherwise indicated, the term "substituted amino" as employed herein alone or as part of another group refers to amino substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. These substituents may be further substituted with a carboxylic acid and/or any of the substituents for alkyl as set out above. In addition, the amino substituents may be taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy.

Unless otherwise indicated, the term "lower alkylthio", "alkylthio", "arylthio" or "aralkylthio" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.


Unless otherwise indicated, the term "lower alkylamino", "alkylamino", "arylamino", or "arylalkylamino" as employed herein alone or as part of another group includes any of the above alkyl, aryl or arylalkyl groups linked to a nitrogen atom.

Unless otherwise indicated, the term "acyl" as employed herein by itself or part of another group, as defined herein, refers to an organic radical linked to a

carbonyl $\left(\begin{array}{c} \text{O} \\ \parallel \\ \text{C} \end{array} \right)$ group; examples of acyl groups include any of the R groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cycloheteroalkanoyl and the like.

Unless otherwise indicated, the term "cycloheteroalkyl" as used herein alone or as part of another group refers to a 5-, 6- or 7-membered saturated or partially




unsaturated ring which includes 1 to 2 hetero atoms such as nitrogen, oxygen and/or sulfur, linked through a carbon atom or a heteroatom, where possible, optionally via the linker $(CH_2)_p$ (where p is 0, 1, 2 or 3), such as






and the like. The above groups may include 1 to 4 substituents such as alkyl, halo, oxo and/or any of the substituents for alkyl or aryl set out herein. In addition, any of the cycloheteroalkyl rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

Unless otherwise indicated, the term "heteroaryl" as used herein alone or as part of another group refers to a 5-, 6- or 7- membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), and includes possible N-oxides, linked through a carbon atom or a heteroatom, where possible, optionally via the linker $(CH_2)_q$ (where q is 0, 1, 2 or 3). The heteroaryl group may optionally include 1 to 4 substituents such as any of the substituents for alkyl or aryl set out above. Examples of heteroaryl groups include the following:

25



5



and the like.

10 Examples of A rings and B rings include, but are not limited to any of the 6-
membered heteroaryl groups as defined above, 6- membered cycloheteroalkyl groups
as defined above, and 6- membered aryl groups as defined above.


The term "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to a (CH₂)_p chain.

The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C atom or heteroatom to a $-(CH_2)_q-$ chain, alkylene or alkenylene as defined above.

The term "polyhaloalkyl" as used herein refers to an "alkyl" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF₃CH₂, CF₃ or CF₃CF₂CH₂.


5 The term "polyhaloalkyloxy" as used herein refers to an "alkoxy" or "alkyloxy" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF₃CH₂O, CF₃O or CF₃CF₂CH₂O.

The term "prodrug esters" as employed herein includes prodrug esters which are known in the art for carboxylic and phosphorus acid esters such as methyl, ethyl, 10 benzyl and the like. Other prodrug ester examples include the following groups: (1-alkanoyloxy)alkyl such as,





15 wherein R^z, R^t and R^y are H, alkyl, aryl or arylalkyl; however, R^zO cannot be HO.

Examples of such prodrug esters include



20 Other examples of suitable prodrug esters include





wherein R^Z can be H, alkyl (such as methyl or t-butyl), arylalkyl (such as benzyl) or aryl (such as phenyl); R^V is H, alkyl, halogen or alkoxy, R^U is alkyl, aryl, arylalkyl or alkoxy, and n_1 is 0, 1 or 2.

The terms pharmaceutically acceptable “salt” and “salts” refer to basic salts formed with inorganic and organic bases. Such salts include ammonium salts; alkali metal salts, such as lithium, sodium and potassium salts (which are preferred); alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as amine like salts (e.g., dicyclohexylamine salt, benzathine, N-methyl-D-glucamine, and hydrabamine salts); and salts with amino acids like arginine, lysine and the like; and zwitterions, the so-called “inner salts”. Nontoxic, pharmaceutically acceptable salts are preferred, although other salts are also useful, e.g., in isolating or purifying the product.

The term pharmaceutically acceptable “salt” and “salts” also includes acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid such as HCl or HBr, with strong organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C1-C4) alkyl or arylsulfonic acids which are unsubstituted or substituted, for example by halogen, for example methanesulfonic acid or p-toluenesulfonic acid.

All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including

any one or the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by
5 conventional methods for example, chromatographic or fractional crystallization.

Combinations

Where desired, the compounds of structure I may be used in combination with one or more other types of therapeutic agents such as immunosuppressants, anticancer
10 agents, anti-viral agents, anti-inflammatory agents, anti-fungal agents, antibiotics, anti-vascular hyperproliferation agents, anti-depressive agents, hypolipidemic agents or lipid-lowering agents or lipid modulating agents, antidiabetic agents, anti-obesity agents, antihypertensive agents, platelet aggregation inhibitors, and/or anti-osteoporosis agents, which may be administered orally in the same dosage form, in a
15 separate oral dosage form or by injection.

The immunosuppressants which may be optionally employed in combination with compounds of formula I of the invention include cyclosporins, for example cyclosporin A, mycophenolate, interferon-beta, deoxyspergolin, FK-506 or Ant.-IL-2.

The anti-cancer agents which may be optionally employed in combination
20 with compounds of formula I of the invention include azathioprine, 5-fluorouracil, cyclophosphamide, cisplatin, methotrexate, thiotepa, carboplatin, and the like.

The anti-viral agents which may be optionally employed in combination with compounds of formula I of the invention include abacavir, aciclovir, ganciclovir, zidancin, vidarabine, and the like.

25 The anti-inflammatory agents which may be optionally employed in combination with compounds of formula I of the invention include non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, cox-2 inhibitors such as celecoxib, rofecoxib, aspirin, naproxen, ketoprofen, diclofenac sodium, indomethacin, piroxicam, steroids such as prednisone, dexamethasone, hydrocortisone,
30 triamcinolone diacetate, gold compounds, such as gold sodium thiomalate, TNF- α inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or Rapamune) or derivatives thereof, infliximab (Remicade®

Centocor, Inc.). CTLA-4Ig, LEA29Y, antibodies such as anti-ICAM-3, anti-IL-2 receptor (Anti-Tac), anti-CD45RB, anti-CD2, anti-CD3 (OKT-3), anti-CD4, anti-CD80, anti-CD86, monoclonal antibody OKT3, agents blocking the interaction between CD40 and CD154 (a.k.a. "gp39"), such as antibodies specific for CD40
5 and/or CD154, fusion proteins such as etanercept, fusion proteins constructed from CD40 and/or CD154gp39 (e.g. CD40Ig and CD8gp39), inhibitors, such as nuclear translocation inhibitors, of NF-kappa B function, such as deoxyspergualin (DSG).

The anti-fungal agents which may be optionally employed in combination with compounds of formula I of the invention include fluconazole, miconazole,
10 amphotericin B, and the like.

The antibiotics which may be optionally employed in combination with compounds of formula I of the invention include penicillin, tetracycline, amoxicillin, ampicillin, erythromycin, doxycycline, vancomycin, minocycline, clindamycin or cefalexin.

15 The anti-vascular hyperproliferation agents which may be optionally employed with compounds of formula I of the invention include methotrexate, leflunomide, FK506 (tacrolimus, Prograf),


The hypolipidemic agent or lipid-lowering agent or lipid modulating agents which may be optionally employed in combination with the compounds of formula I
20 of the invention may include 1,2,3 or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibric acid derivatives, ACAT inhibitors, lipoxxygenase inhibitors, cholesterol absorption inhibitors, ileal Na⁺/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, bile acid sequestrants, and/or nicotinic acid and derivatives thereof.

25 MTP inhibitors employed herein include MTP inhibitors disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Application Serial No. 09/175,180 filed October 20, 1998, now U.S. Patent No. 5,962,440. Preferred are each of the preferred MTP inhibitors disclosed in each of the
30 above patents and applications.

All of the above U.S. Patents and applications are incorporated herein by reference.

Most preferred MTP inhibitors to be employed in accordance with the present invention include preferred MTP inhibitors as set out in U.S. Patent Nos. 5,739,135 and 5,712,279, and U.S. Patent No. 5,760,246.

The most preferred MTP inhibitor is 9-[4-[4-[[2-(2,2,2-trifluoroethoxy)benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide



The hypolipidemic agent may be an HMG CoA reductase inhibitor which includes, but is not limited to, mevastatin and related compounds as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in U.S. Patent No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Patent No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Patent No. 5,354,772, cerivastatin disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Patent Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, itavastatin (Nissan/Sankyo's nisvastatin (NK-104)) disclosed in U.S. Patent No. 5,011,930, Shionogi-Astra/Zeneca visastatin (ZD-4522) disclosed in U.S. Patent No. 5,260,440, and related statin compounds disclosed in U.S. Patent No. 5,753,675, pyrazole analogs of mevalonolactone derivatives as disclosed in U.S. Patent No. 4,613,610, indene analogs of mevalonolactone derivatives as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl]pyran-2-ones and derivatives thereof as disclosed in U.S. Patent No. 4,647,576, Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of

mevalonolactone as disclosed in PCT application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed in French Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan and thiophene derivatives as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Patent No. 4,686,237, octahydronaphthalenes such as disclosed in U.S. Patent No. 4,499,289, keto analogs of mevinolin (lovastatin) as disclosed in European Patent Application No. 0,142,146 A2, and quinoline and pyridine derivatives disclosed in U.S. Patent No. 5,506,219 and 5,691,322.

In addition, phosphinic acid compounds useful in inhibiting HMG CoA reductase suitable for use herein are disclosed in GB 2205837.

The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α -phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those disclosed by Biller et al, J. Med. Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinyl-methyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Patent No. 4,871,721 and 4,924,024 and in Biller, S.A., Neuenschwander, K., Ponpipom, M.M., and Poulter, C.D., Current Pharmaceutical Design, 2, 1-40 (1996).

In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary.

Other hypolipidemic agents suitable for use herein include, but are not limited to, fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Patent No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex®, Policexide®) and cholestagel (Sankyo/Geltex), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402),

tetrahydrolipstatin (THL), istigmantylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (niacin), acipimox, acifran, 5 neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U.S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents.

The hypolipidemic agent may be an ACAT inhibitor such as disclosed in, 10 Drugs of the Future 24, 9-15 (1999), (Avasimibe); "The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al, Atherosclerosis (Shannon, Ireland). (1998), 137(1), 77-85; "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of 15 ApoB100-containing lipoprotein", Ghiselli, Giancarlo, Cardiovasc. Drug Rev. (1998), 16(1), 16-30; "RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", Smith, C., et al, Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals", Krause et al, Editor(s): Ruffolo, Robert R., Jr.; 20 Hollinger, Manfred A., Inflammation: Mediators Pathways (1995), 173-98, Publisher: CRC, Boca Raton, Fla.; "ACAT inhibitors: potential anti-atherosclerotic agents", Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25; "Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl- 25 CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity", Stout et al, Chemtracts: Org. Chem. (1995), 8(6), 359-62, or TS-962 (Taisho Pharmaceutical Co. Ltd).

The hypolipidemic agent may be an upregulator of LDL receptor activity such 30 as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly).

The hypolipidemic agent may be a cholesterol absorption inhibitor preferably Schering-Plough's ezetimibe (SCH58235) and SCH48461 as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998).

5 The hypolipidemic agent may be an ileal Na⁺/bile acid cotransporter inhibitor such as disclosed in Drugs of the Future, 24, 425-430 (1999).

The lipid-modulating agent may be a cholesteryl ester transfer protein (CETP) inhibitor such as Pfizer's CP 529,414 (WO/0038722 and EP 818448) and Pharmacia's SC-744 and SC-795.

10 The ATP citrate lyase inhibitor which may be employed in the combination of the invention may include, for example, those disclosed in U.S. Patent No. 5,447,954.

Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, itavastatin and visastatin and ZD-4522.

15 The above-mentioned U.S. patents are incorporated herein by reference. The amounts and dosages employed will be as indicated in the Physician's Desk Reference and/or in the patents set out above.

The compounds of formula I of the invention will be employed in a weight ratio to the hypolipidemic agent (were present), within the range from about 500:1 to about 1:500, preferably from about 100:1 to about 1:100.

20 The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.

The dosages and formulations for the hypolipidemic agent will be as disclosed in the various patents and applications discussed above.

25 The dosages and formulations for the other hypolipidemic agent to be employed, where applicable, will be as set out in the latest edition of the Physicians' Desk Reference.

For oral administration, a satisfactory result may be obtained employing the MTP inhibitor in an amount within the range of from about 0.01 mg to about 500 mg and preferably from about 0.1 mg to about 100 mg, one to four times daily.

30 A preferred oral dosage form, such as tablets or capsules, will contain the MTP inhibitor in an amount of from about 1 to about 500 mg, preferably from about 2

to about 400 mg, and more preferably from about 5 to about 250 mg, one to four times daily.

For oral administration, a satisfactory result may be obtained employing an HMG CoA reductase inhibitor, for example, pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin in dosages employed as indicated in the Physician's Desk Reference, such as in an amount within the range of from about 1 to 2000 mg, and preferably from about 4 to about 200 mg.

The squalene synthetase inhibitor may be employed in dosages in an amount within the range of from about 10 mg to about 2000 mg and preferably from about 25 mg to about 200 mg.

A preferred oral dosage form, such as tablets or capsules, will contain the HMG CoA reductase inhibitor in an amount from about 0.1 to about 100 mg, preferably from about 0.5 to about 80 mg, and more preferably from about 1 to about 40 mg.

A preferred oral dosage form, such as tablets or capsules will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg.

The hypolipidemic agent may also be a lipoxxygenase inhibitor including a 15-lipoxxygenase (15-LO) inhibitor such as benzimidazole derivatives as disclosed in WO 97/12615, 15-LO inhibitors as disclosed in WO 97/12613, isothiazolones as disclosed in WO 96/38144, and 15-LO inhibitors as disclosed by Sendobry et al "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxxygenase inhibitor lacking significant antioxidant properties", Brit. J. Pharmacology (1997) 120, 1199-1206, and Cornicelli et al, "15-Lipoxxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease", Current Pharmaceutical Design, 1999, 5, 11-20.

The compounds of formula I and the hypolipidemic agent may be employed together in the same oral dosage form or in separate oral dosage forms taken at the same time.

The compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be

advisable to start a patient on a low dose combination and work up gradually to a high dose combination.

The preferred hypolipidemic agent is pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin or cerivastatin as well as niacin and/or cholestagel.

5 The other antidiabetic agent which may be optionally employed in combination with the compound of formula I may be 1,2,3 or more antidiabetic agents or antihyperglycemic agents including insulin secretagogues or insulin sensitizers, or other antidiabetic agents preferably having a mechanism of action different from the compounds of formula I of the invention, which may include biguanides, sulfonyl
10 ureas, glucosidase inhibitors, PPAR γ agonists, such as thiazolidinediones, α P2 inhibitors, dipeptidyl peptidase IV (DP4) inhibitors, SGLT2 inhibitors, and/or meglitinides, as well as insulin, and/or glucagon-like peptide-1 (GLP-1).

 The other antidiabetic agent may be an oral antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof, preferably
15 metformin HCl.

 Where the antidiabetic agent is a biguanide, the compounds of structure I will be employed in a weight ratio to biguanide within the range from about 0.001:1 to about 10:1, preferably from about 0.01:1 to about 5:1.

 The other antidiabetic agent may also preferably be a sulfonyl urea such as
20 glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Patent No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the β -cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral dosage forms.

25 The compounds of structure I will be employed in a weight ratio to the sulfonyl urea in the range from about 0.01:1 to about 100:1, preferably from about 0.02:1 to about 5:1.

 The oral antidiabetic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Patent No. 4,904,769) or miglitol (disclosed in U.S. Patent
30 No. 4,639,436), which may be administered in the same or in a separate oral dosage forms.

The compounds of structure I will be employed in a weight ratio to the glucosidase inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.05:1 to about 10:1.

The compounds of structure I may be employed in combination with a PPAR γ agonist such as a thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as troglitazone (Warner-Lambert's Rezulin[®], disclosed in U.S. Patent No. 4,572,912), rosiglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 5,594,016), Glaxo-Wellcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 (Dr. Reddy/NN), or YM-440 (Yamanouchi), preferably rosiglitazone and pioglitazone.

The compounds of structure I will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably from about 0.05 to about 10:1.

The sulfonyl urea and thiazolidinedione in amounts of less than about 150 mg oral antidiabetic agent may be incorporated in a single tablet with the compounds of structure I.

The compounds of structure I may also be employed in combination with an antihyperglycemic agent such as insulin or with glucagon-like peptide-1 (GLP-1) such as GLP-1(1-36) amide, GLP-1(7-36) amide, GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener, the disclosure of which is incorporated herein by reference), as well as AC2993 (Amylin) and LY-315902 (Lilly), which may be administered via injection, intranasal, inhalation or by transdermal or buccal devices.

Where present, metformin, the sulfonyl ureas, such as glyburide, glimepiride, glipizide, glipizide, chlorpropamide and gliclazide and the glucosidase inhibitors acarbose or miglitol or insulin (injectable, pulmonary, buccal, or oral) may be employed in formulations as described above and in amounts and dosing as indicated in the Physician's Desk Reference (PDR).

Where present, metformin or salt thereof may be employed in amounts within the range from about 500 to about 2000 mg per day which may be administered in single or divided doses one to four times daily.

Where present, the thiazolidinedione anti-diabetic agent may be employed in
5 amounts within the range from about 0.01 to about 2000 mg/day which may be administered in single or divided doses one to four times per day.

Where present insulin may be employed in formulations, amounts and dosing as indicated by the Physician's Desk Reference.

Where present GLP-I peptides may be administered in oral buccal
10 formulations, by nasal administration or parenterally as described in U.S. Patent Nos. 5,346,701 (TheraTech), 5,614,492 and 5,631,224 which are incorporated herein by reference.

The other antidiabetic agent may also be a PPAR α/γ dual agonist such as AR-HO39242 (Astra/Zeneca), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck)
15 as well as those disclosed by Murakami et al, "A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation-Activated Receptor Alpha (PPAR alpha) and PPAR gamma. Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes 47, 1841-1847 (1998).

The antidiabetic agent may be an SGLT2 inhibitor such as disclosed in U.S.
20 application Serial No. 09/679,027, filed October 4, 2000 (attorney file LA49 NP), employing dosages as set out therein. Preferred are the compounds designated as preferred in the above application.

The antidiabetic agent may be an $\alpha P2$ inhibitor such as disclosed in U.S.
application Serial No. 09/391,053, filed September 7, 1999, and in U.S. application
25 Serial No. 09/519,079, filed March 6, 2000 (attorney file LA27 NP), employing dosages as set out herein. Preferred are the compounds designated as preferred in the above application.

The antidiabetic agent may be a DP4 inhibitor such as disclosed in U.S.
application Serial No. 09/788,173 filed February 16, 2001 (attorney file LA50),
30 WO99/38501, WO99/46272, WO99/67279 (PROBIODRUG), WO99/67278 (PROBIODRUG), WO99/61431 (PROBIODRUG), NVP-DPP728A (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine) (Novartis)

(preferred) as disclosed by Hughes et al, Biochemistry, 38(36), 11597-11603, 1999, TSL-225 (tryptophyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (disclosed by Yamada et al, Bioorg. & Med. Chem. Lett. 8 (1998) 1537-1540, 2-cyanopyrrolidides and 4-cyanopyrrolidides as disclosed by Ashworth et al, Bioorg. & Med. Chem. Lett.,
5 Vol. 6, No. 22, pp 1163-1166 and 2745-2748 (1996) employing dosages as set out in the above references.

The meglitinide which may optionally be employed in combination with the compound of formula I of the invention may be repaglinide, nateglinide (Novartis) or KAD1229 (PF/Kissei), with repaglinide being preferred.

10 . The compound of formula I will be employed in a weight ratio to the meglitinide, PPAR γ agonist, PPAR α/γ dual agonist, $\alpha P2$ inhibitor, DP4 inhibitor or SGLT2 inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.05 to about 10:1.

The other type of therapeutic agent which may be optionally employed with a
15 compound of formula I may be 1, 2, 3 or more of an anti-obesity agent including a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, an $\alpha P2$ inhibitor, a thyroid receptor agonist and/or an anorectic agent.

The beta 3 adrenergic agonist which may be optionally employed in combination with a compound of formula I may be AJ9677 (Takeda/Dainippon),
20 L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, with AJ9677, L750,355 and CP331648 being preferred.

The lipase inhibitor which may be optionally employed in combination with a compound of formula I may be orlistat or ATL-962 (Alizyme), with orlistat being
25 preferred.

The serotonin (and dopamine) reuptake inhibitor which may be optionally employed in combination with a compound of formula I may be sibutramine, topiramate (Johnson & Johnson) or axokine (Regeneron), with sibutramine and topiramate being preferred.

30 The thyroid receptor agonist which may be optionally employed in combination with a compound of formula I may be a thyroid receptor ligand as disclosed in WO97/21993 (U. Cal SF), WO99/00353 (KaroBio), GB98/284425

(KaroBio), and U.S. Provisional Application 60/183,223 filed February 17, 2000, with compounds of the KaroBio applications and the above U.S. provisional application being preferred.

5 The anorectic agent which may be optionally employed in combination with a compound of formula I may be dexamphetamine, phentermine, phenylpropanolamine or mazindol, with dexamphetamine being preferred.

 The various anti-obesity agents described above may be employed in the same dosage form with the compound of formula I or in different dosage forms, in dosages and regimens as generally known in the art or in the PDR.

10 The antihypertensive agents which may be employed in combination with the compound of formula I of the invention include ACE inhibitors, angiotensin II receptor antagonists, NEP/ACE inhibitors, as well as calcium channel blockers, β -adrenergic blockers and other types of antihypertensive agents including diuretics.

 The angiotensin converting enzyme inhibitor which may be employed herein
15 includes those containing a mercapto (-S-) moiety such as substituted proline derivatives, such as any of those disclosed in U.S. Pat. No. 4,046,889 to Ondetti et al mentioned above, with captopril, that is, 1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline, being preferred, and mercaptoacyl derivatives of substituted prolines such as any of those disclosed in U.S. Pat. No. 4,316,906 with zofenopril being preferred.

20 Other examples of mercapto containing ACE inhibitors that may be employed herein include rentiapril (fentiapril, Santen) disclosed in Clin. Exp. Pharmacol. Physiol. 10:131 (1983); as well as pivopril and YS980.

 Other examples of angiotensin converting enzyme inhibitors which may be employed herein include any of those disclosed in U.S. Pat. No. 4,374,829 mentioned
25 above, with N-(1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline, that is, enalapril, being preferred, any of the phosphonate substituted amino or imino acids or salts disclosed in U.S. Pat. No. 4,452,790 with (S)-1-[6-amino-2-[[hydroxy-(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline or (ceronapril) being preferred, phosphinylalkanoyl prolines disclosed in U.S. Pat. No. 4,168,267 mentioned above
30 with fosinopril being preferred, any of the phosphinylalkanoyl substituted prolines disclosed in U.S. Pat. No. 4,337,201, and the phosphonamidates disclosed in U.S. Pat. No. 4,432,971 discussed above.

Other examples of ACE inhibitors that may be employed herein include Beecham's BRL 36,378 as disclosed in European Patent Application Nos. 80822 and 60668; Chugai's MC-838 disclosed in C.A. 102:72588v and Jap. J. Pharmacol. 40:373 (1986); Ciba-Geigy's CGS 14824 (3-([1-ethoxycarbonyl-3-phenyl-(1S)-propyl]amino)-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1 acetic acid HCl) disclosed in U.K. Patent No. 2103614 and CGS 16,617 (3(S)-[[[(1S)-5-amino-1-carboxypentyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid) disclosed in U.S. Pat. No. 4,473,575; cetapril (alacepril, Dainippon) disclosed in Eur. Therap. Res. 39:671 (1986); 40:543 (1986); ramipril (Hoechst) disclosed in Euro. Patent No. 79-022 and Curr. Ther. Res. 40:74 (1986); Ru 44570 (Hoechst) disclosed in Arzneimittelforschung 34:1254 (1985), cilazapril (Hoffman-LaRoche) disclosed in J. Cardiovasc. Pharmacol. 9:39 (1987); R 31-2201 (Hoffman-LaRoche) disclosed in FEBS Lett. 165:201 (1984); lisinopril (Merck), indalapril (delapril) disclosed in U.S. Pat. No. 4,385,051; indolapril (Schering) disclosed in J. Cardiovasc. Pharmacol. 5:643, 655 (1983), spirapril (Schering) disclosed in Acta. Pharmacol. Toxicol. 59 (Supp. 5):173 (1986); perindopril (Servier) disclosed in Eur. J. clin. Pharmacol. 31:519 (1987); quinapril (Warner-Lambert) disclosed in U.S. Pat. No. 4,344,949 and CI925 (Warner-Lambert) ([3S-[2[R(*)R(*)]]3R(*)]-2-[2-[[1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid HCl) disclosed in Pharmacologist 26:243, 266 (1984), WY-44221 (Wyeth) disclosed in J. Med. Chem. 26:394 (1983).

Preferred ACE inhibitors are captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril and moexipril.

NEP/ACE inhibitors may also be employed herein in that they possess neutral endopeptidase (NEP) inhibitory activity and angiotensin converting enzyme (ACE) inhibitory activity. Examples of NEP/ACE inhibitors suitable for use herein include those disclosed in U.S. Pat. No.s. 5,362,727, 5,366,973, 5,225,401, 4,722,810, 5,223,516, 4,749,688, U.S. Patent. No. 5,552,397, U.S. Pat. No. 5,504,080, U.S. Patent No. 5,612,359, U.S. Pat. No. 5,525,723, European Patent Application 0599,444, 0481,522, 0599,444, 0595,610, European Patent Application 0534363A2, 534,396 and 534,492, and European Patent Application 0629627A2.

Preferred are those NEP/ACE inhibitors and dosages thereof which are designated as preferred in the above patents/applications which U.S. patents are incorporated herein by reference; most preferred are omapatrilat, BMS 189,921 ([S-(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid (gemopatrilat)) and CGS 30440.

The angiotensin II receptor antagonist (also referred to herein as angiotensin II antagonist or AII antagonist) suitable for use herein includes, but is not limited to, irbesartan, losartan, valsartan, candesartan, telmisartan, tasosartan or eprosartan, with irbesartan, losartan or valsartan being preferred.

A preferred oral dosage form, such as tablets or capsules, will contain the ACE inhibitor or AII antagonist in an amount within the range from about 0.1 to about 500 mg, preferably from about 5 to about 200 mg and more preferably from about 10 to about 150 mg.

For parenteral administration, the ACE inhibitor, angiotensin II antagonist or NEP/ACE inhibitor will be employed in an amount within the range from about 0.005 mg/kg to about 10 mg/kg and preferably from about 0.01 mg/kg to about 1 mg/kg.

Where a drug is to be administered intravenously, it will be formulated in conventional vehicles, such as distilled water, saline, Ringer's solution or other conventional carriers.

It will be appreciated that preferred dosages of ACE inhibitor and AII antagonist as well as other antihypertensives disclosed herein will be as set out in the latest edition of the Physician's Desk Reference (PDR).

Other examples of preferred antihypertensive agents suitable for use herein include omapatrilat (Vanlev®) amlodipine besylate (Norvasc®), prazosin HCl (Minipress®), verapamil, nifedipine, nadolol, diltiazem, felodipine, nisoldipine, isradipine, nicardipine, atenolol, carvedilol, sotalol, terazosin, doxazosin, propranolol, and clonidine HCl (Catapres®).

Diuretics which may be employed in combination with compounds of formula I include hydrochlorothiazide, torasemide, furosemide, spironolactone, and indapamide.

Antiplatelet agents which may be employed in combination with compounds of formula I of the invention include aspirin, clopidogrel, ticlopidine, dipyridamole, abciximab, tirofiban, eptifibatide, anagrelide, and ifetroban, with clopidogrel and aspirin being preferred.

- 5 The antiplatelet drugs may be employed in amounts as indicated in the PDR. Ifetroban may be employed in amounts as set out in U.S. Patent No. 5,100,889.

Antiosteoporosis agents suitable for use herein in combination with the compounds of formula I of the invention include parathyroid hormone or bisphosphonates, such as MK-217 (alendronate) (Fosamax®).

- 10 Dosages employed for the above drugs will be as set out in the Physician's Desk Reference.

PHARMACEUTICAL FORMULATIONS

- 15 The pharmaceutical composition of the invention includes a pharmaceutically acceptable carrier, adjuvant or vehicle that may be administered to a subject, together with a compound of the present invention, and which does not destroy the pharmacological activity thereof. Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, the following: ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems ("SEDDS") such as d(-tocopherol polyethyleneglycol 1000 succinate), surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
- 25 Cyclodextrins such as α -, β - and γ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- β -
- 30

cyclodextrins, or other solubilized derivatives may also be used to enhance delivery of the modulators of the present invention.

The compositions of the present invention may contain other therapeutic agents as described below, and may be formulated, for example, by employing
5 conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.

The compounds of the invention may be administered by any suitable means,
10 for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such
15 as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The compounds of the invention may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions including the compounds of the invention,
20 or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The compounds of the invention may also be administered liposomally.

Exemplary compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid
25 or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The
30 present compounds may also be delivered through the oral cavity by sublingual and/or buccal administration. Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used. Exemplary compositions include those

formulating the compound(s) of the invention with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (Avicel) or polyethylene glycols (PEG). Such formulations may also include an excipient to aid mucosal
5 adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g., Carbopol 934). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

10 Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.

Exemplary compositions for parenteral administration include injectable
15 solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid. The term "parenteral" as used herein includes
20 subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

Exemplary compositions for rectal administration include suppositories which may contain, for example, a suitable non-irritating excipient, such as cocoa butter,
25 synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquify and/or dissolve in the rectal cavity to release the drug.

Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).

The effective amount of a compound of the present invention may be
30 determined by one of ordinary skill in the art, and includes exemplary dosage amounts for an adult human of from about 0.1 to 500 mg/kg of body weight of active compound per day, or between 5 and 2000 mg per day which may be administered in

a single dose or in the form of individual divided doses, such as from 1 to 5 times per day. It will be understood that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of
5 action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition. Preferred subjects for treatment include animals, most preferably mammalian species such as humans, and domestic animals such as dogs, cats and the like.

10 A typical capsule for oral administration contains compounds of structure I (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.

A typical injectable preparation is produced by aseptically placing 250 mg of compounds of structure I into a vial, aseptically freeze-drying and sealing. For use,
15 the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

The compounds of formula I of the invention are glucocorticoid receptor modulators as shown by their ability to bind glucocorticoid receptors in GR binding assays.

20 Compounds of formula I of the invention may also inhibit AP-1 activity as indicated in cellular transrespositional assays, and cause none to minimal transactivation as indicated in cellular transscriptional assays.

The GR binding assay, cellular transrespositional assay and cellular transcriptional assay employed are described in copending provisional application No.
25 60/396,907, filed July 18, 2002 (attorney docket D0250 PSP) which is incorporated herein by reference.

The following abbreviations are employed in the Examples:

Ph = phenyl

Bn = benzyl

30 t-Bu = tertiary butyl

Me = methyl

Et = ethyl

TMS = trimethylsilyl

TMSN₃ = trimethylsilyl azide

TBS = tert-butyldimethylsilyl

Fmoc = fluorenylmethoxycarbonyl

5 Boc = tert-butoxycarbonyl

Cbz = carbobenzyloxy or carbobenzoxy or benzyloxycarbonyl

THF = tetrahydrofuran

Et₂O = diethyl ether

hex = hexanes

10 EtOAc = ethyl acetate

DMF = dimethyl formamide

MeOH = methanol

EtOH = ethanol

i-PrOH = isopropanol

15 DMSO = dimethyl sulfoxide

DME = 1,2 dimethoxyethane

DCE = 1,2 dichloroethane

HMPA = hexamethyl phosphoric triamide

HOAc or AcOH = acetic acid

20 TFA = trifluoroacetic acid

TFAA = trifluoroacetic anhydride

i-Pr₂NEt = diisopropylethylamine

Et₃N = triethylamine

NMM = N-methyl morpholine

25 DMAP = 4-dimethylaminopyridine

NaBH₄ = sodium borohydride

NaBH(OAc)₃ = sodium triacetoxyborohydride

DIBALH = diisobutyl aluminum hydride

LAH or LiAlH₄ = lithium aluminum hydride

30 n-BuLi = n-butyllithium

LDA = lithium diisopropylamide

Pd/C = palladium on carbon

- PtO₂ = platinum oxide
KOH = potassium hydroxide
NaOH = sodium hydroxide
LiOH = lithium hydroxide
- 5 K₂CO₃ = potassium carbonate
NaHCO₃ = sodium bicarbonate
DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene
EDC (or EDC.HCl) or EDCI (or EDCI.HCl) or EDAC = 3-ethyl-3'-(dimethylamino)propyl- carbodiimide hydrochloride (or 1-(3-dimethylaminopropyl)-
- 10 3-ethylcarbodiimide hydrochloride)
HOBT or HOBT.H₂O = 1-hydroxybenzotriazole hydrate
HOAT = 1-Hydroxy-7-azabenzotriazole
BOP reagent = benzotriazol-1-yloxy-tris (dimethylamino) phosphonium hexafluorophosphate
- 15 NaN(TMS)₂ = sodium hexamethyldisilazide or sodium bis(trimethylsilyl)amide
Ph₃P = triphenylphosphine
Pd(OAc)₂ = Palladium acetate
(Ph₃P)₄Pd⁰ = tetrakis triphenylphosphine palladium
DEAD = diethyl azodicarboxylate
- 20 DIAD = diisopropyl azodicarboxylate
Cbz-Cl = benzyl chloroformate
CAN = ceric ammonium nitrate
SAX = Strong Anion Exchanger
SCX = Strong Cation Exchanger
- 25 Ar = argon
N₂ = nitrogen
min = minute(s)
h or hr = hour(s)
L = liter
- 30 mL = milliliter
μL = microliter
g = gram(s)

mg = milligram(s)

mol = moles

mmol = millimole(s)

meq = milliequivalent

5 RT = room temperature

sat or sat'd = saturated

aq. = aqueous

TLC = thin layer chromatography

HPLC = high performance liquid chromatography

10 LC/MS = high performance liquid chromatography/mass spectrometry

MS or Mass Spec = mass spectrometry

NMR = nuclear magnetic resonance

NMR spectral data: s = singlet; d = doublet; m = multiplet; br = broad; t = triplet


mp = melting point

15

Preparations

The preparations set out below are for the synthesis of reagents that were not obtained from commercial sources and were employed for the preparation of compounds of formula I of the invention. All chemical structures in the tables and

20 schemes are racemic unless specified otherwise.

Preparation 12-Amino-4-[1-(4-fluoro)naphthyl]thiazole 1a

25

Step 1

To a solution of 4'-fluoro-1'-acetonaphthone (28.69 mmol, 5.4 g) in 1,4-dioxane (18.0 mL) at 0° C was added bromine (35.13 mmol, 5.61 g). After 3 hours at room temperature the reaction mixture was concentrated in vacuo to give 7.66 g (Y: 100%) of the product of step 1.












Step 2

To a solution of the product of step 1 (28.69 mmol, 7.66 g) in ethyl alcohol (20 mL) at room temperature was added thiourea (36.13 mmol, 2.75 g). After 1 hour at room temperature a precipitate formed. To the reaction mixture was added water (100 mL) and the solid was collected by vacuum filtration. The solid was then washed with water (3 x 100 mL) and dichloromethane (3 x 100 mL). The solid was then dried in vacuo to give 5.5 g (Y: 75%) of the title compound 1a. MS (E+) *m/z*: 245 (MH⁺).

15

In a similar manner the following compounds were prepared from the corresponding ketone.


Preparation	Structure
1b	
1c	
1d	
1e	
1f	

Preparation	Structure
1g	
1h	
1i	
1j	
1k	
1l	
1m	
1n	
1o	
1p	
1q	

Preparation	Structure
1r	
1s	
1t	
1u	
1v	
1w	

Preparation 2

2-Amino-4-[1-(4-fluoro)naphthyl]imidazole 2a







Step 1


To a solution of the product of preparation 1a, step 1 (18.73 mmol, 5.0 g) in DMF (15 mL) at room temperature was added 1-acetylguanidine (57.43 mmol, 5.80 g). After 5 hours at room temperature, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The organic phases were concentrated in vacuo and the residue chromatographed on silica gel (eluted with 5% methanol in dichloromethane) to give 2.0 g (Y: 39%) of the product of step 1. MS (E+) m/z : 270 (MH⁺).

10 Step 2

To a solution of the product of step 1 (7.43 mmol, 2.0 g) in methanol (17 mL) was added water (8.5 mL) and 12 N HCl (12.0 mL). After 1 hour at reflux the reaction mixture was concentrated in vacuo to approximately 15 mL. The resulting solution was then purified and neutralized by cation exchange SPE to give 1.66 g (Y: 99%) of the title compound **2a**. MS (E+) m/z : 228 (MH⁺).

In a similar manner the following compounds were prepared from the corresponding ketones.

Preparation	Structure
2b	
2c	
2d	
2e	

Preparation 32-Amino-4-(1-naphthyl)oxazole 3a

5

Step 1

To a solution of 1-acetonaphthone (29.38 mmol, 5.0 g) in glacial acetic acid (10.0 mL) at RT was added bromine (30.06 mmol, 4.80 g) in glacial acetic acid (5.0 mL). After 5 minutes the reaction mixture was poured onto crushed ice and extracted with dichloromethane to give 7.31 g (Y: 100%) of the product of step 1. MS (E+) m/z : 250 (MH^+).


10

Step 2

To a solution of the product of step 1 (5.50 mmol, 1.37 g) in ethyl alcohol (10 mL) was added urea (27.50 mmol, 1.65 g). After 2 hours at reflux the reaction mixture was concentrated in vacuo and the residue chromatographed on silica gel (eluted with 30% ethyl acetate in hexane) to give 100 mg (Y: 9%) of the title compound **3a**. MS (E+) m/z : 211 (MH^+).

15

20

Preparation 45-(1-Naphthyl)-3-aminoisoxazole 4a


Step 1

To a solution of acetonitrile (12.18 mmol, 0.50 g) in THF (10.0 mL) was added 60% sodium hydride (24.36 mmol, 0.975 g), followed by 1-naphthoic acid methyl ester (12.18 mmol, 2.27 g). After 2 hours at 70 °C the reaction mixture was quenched with an excess of 1N HCl and extracted with dichloromethane (3 x 30 mL). The organic phases were concentrated in vacuo and the residue was chromatographed on silica gel (eluted with 33% ethyl acetate in hexane) to give 1.80 g (Y: 76%) of the product of step 1. MS (E+) *m/z*: 196 (MH⁺).

10 Step 2

Hydroxylamine sulfate (1.61 mmol, 264 mg) was added to a stirred solution of the product of step 1 (2.94 mmol, 573 mg) and NaOH (3.53 mmol, 141 mg) in 50% aq. EtOH (6.0 mL). The mixture was heated at 80 °C for 5 hours and then stirred at RT for 14 hours. The reaction mixture was quenched with an excess of 1N HCl, washed with dichloromethane (3 x 50 mL), neutralized with saturated sodium bicarbonate solution and extracted with dichloromethane (3 x 50 mL). The organic extracts were combined, dried over Na₂SO₄ and concentrated under vacuo to give 237 mg (Y: 38%) of the title compound **4a**. MS (E+) *m/z*: 211 (MH⁺).

20

Preparation 53-(1-Naphthyl)-5-aminopyrazole 5a


25 To a solution of the product of preparation 4, step 1 (2.70 mmol, 527 mg) in EtOH (5.0 mL) was added hydrazine (2.70 mmol, 85 mg). The resulting mixture was refluxed for 2 h, cooled, diluted with 1N HCl, washed with dichloromethane (3 x 50 mL), neutralized with saturated sodium bicarbonate solution and extracted with

dichloromethane (3 x 50 mL). The organic extracts were combined, dried over Na_2SO_4 and concentrated under vacuum to give 280 mg (Y: 51%) of the title compound 5a. MS (E+) m/z : 210 (MH^+).

5

Preparation 6

4-[1-(6-Methoxy)naphthyl]-2-aminothiazole 6a



10 Step 1

To a solution of 6-methoxy-1-naphthoic acid (0.5 g, 2.47 mmol, 1.0 equi.) in dichloromethane (10 mL) at room temperature was added a solution of oxalyl chloride (2M in dichloromethane, 2.5 mL, 5.0 mmol, 2 equi.). The solution was stirred at room temperature for 2 hours, and the excess oxalyl chloride removed *in vacuo*. The residue was dissolved in methanol and stirred at room temperature for 18 hours. The solvent was removed *in vacuo*, yielding 0.45 g (84%) of the product of step 1: LC/MS (m/z 217, (M-H^+); ^1H NMR (CDCl_3) δ 8.82 (d, 1H), 8.03 (dd, 1H), 7.90 (d, 1H), 7.44 (t, 1H), 7.26 (dd, 1H), 7.16 (s, 1H), 4.02 (s, 3H), 3.95 (s, 3H).

20 Step 2

Reference: P. Chen, P.T. Cheng, S.H. Spergel, R. Zahler, X. Wang, J. Thottathil, J.C. Barrish, R.P. Polniaszek, *Tetrahedron Letters*, **38**, 3175 (1997).

To a solution of the product of step 1 (0.238 g, 1.1 mmol, 1.0 equi.) and chloriodomethane (0.32 mL, 4.4 mmol, 4 equi.) in THF (5 mL) was added a solution of LDA (2M, 2.2 mL, 4.0 equi.) in THF (10 mL) dropwise in 30 minutes, while keeping the solution temperature at -78°C . The reaction solution was stirred at -78°C for 10 minutes. A solution of acetic acid (1.5 mL) in THF (10 mL) was added in dropwise in 10 minutes. After stirring for an additional 10 minutes at -78°C , the solution was quenched with ethyl acetate and saturated sodium chloride solution. The organic phase was washed with saturated sodium bisulfite, saturated sodium chloride, dried with sodium sulfate and concentrated *in vacuo*. The residue was purified by flash chromatography (10% ethyl acetate in hexane) to yield 0.23 g (90%) of the product of step 2: LC/MS (m/z 235, $(\text{M}+\text{H})^{+}$); ^1H NMR (CDCl_3) δ 8.82 (d, 1H), 8.03 (dd, 1H), 7.90 (d, 1H), 7.44 (t, 1H), 7.26 (dd, 1H), 7.16 (s, 1H), 4.80 (s, 2H), 3.95 (s, 3H).

15 Step 3

To a solution of the product of step 2 (0.23 g, 1.0 mmol, 1.0 equi.) in ethanol (5mL) at room temperature was added thiourea (90 mg, 1.2 mmol, 1.2 equi.). The reaction solution was stirred at room temperature for 2 hours, after which a yellow precipitate was formed. The reaction was quenched by addition of water and ethyl acetate. The aqueous phase was extracted with ethyl acetate (3x). The combined organic phases were dried with sodium sulfate and concentrated *in vacuo* to yield 200 mg (78%) of the title compound **6a**: LC/MS (m/z 235, $(\text{M}+\text{H})^{+}$); ^1H NMR (CDCl_3) δ 8.1 (d, 1H), 7.9 (m, 1H), 7.43 (m, 2H), 7.25 (m, 1H), 7.10 (dd, 1H), 6.65 (s, 1H), 3.95 (s, 3H).

25


In a similar manner the following compounds were prepared.

Preparation	Structure
6b	
6c	

Preparation 7

5

4-[1-(6-Methoxy)naphthyl]-2-aminoimidazole 7a




Step 1

10 To a solution of the product of preparation 6, step 2 (0.5 g, 2.14 mmol, 1.0
 15 equi.), in ethanol (5 mL) at room temperature was added 1-acetylguanidine (650 mg,
 6.42 mmol, 3.0 equi.). The reaction solution was stirred at room temperature for 24
 hours. The reaction was quenched by addition of water and ethyl acetate. The
 aqueous phase was extracted with ethyl acetate (3x). The combined organic phases
 were dried with sodium sulfate and concentrated *in vacuo* to yield 0.2 g (35%) of the
 product of step 1: LC/MS (m/z 282, $(M+H)^+$).

Step 2

To a solution of the product of step 1 (0.2 g, 0.7 mmol, 1.0 equi.) in methanol (5 mL) was added water (1.0 mL) and hydrochloric acid (12N, 1.0 mL). The reaction solution was heated to reflux for 1 hour, after which the solvent was removed *in vacuo*. The crude mixture was purified by cation exchange SPE to give 0.12 g (70%) of the title compound **7a**: LC/MS (m/z 240, $(M+H)^+$).

Preparation 84-(3-Pyridyl)-2-aminothiazole **8a**Step 1

To a solution of 3-acetylpyridine (20.0 mmol, 2.42 g) in 48% HBr (10.0 mL) was added bromine (20.0 mmol, 3.2 g) in 48% HBr (4.0 mL). The reaction mixture was heated to 65 °C for one hour and stirred at RT for an additional hour. The reaction mixture was quenched with ice and filtered. The solid was washed with acetone (2 x 10 mL) and diethyl ether (2 x 10 mL). The solid was then dried *in vacuo* to give 3.70 g (Y: 83%) of the product of step 1.

Step 2

To a solution of the product of step 1 (6.10 mmol, 1.22 g) in ethyl alcohol (10 mL) at room temperature was added thiourea (7.32 mmol, 560 mg). After 1 hour at room temperature the reaction mixture was quenched with water (30 mL) and washed with dichloromethane (3 x 100 mL). The aqueous layer was then purified by cation exchange chromatography to give 600 mg (Y: 56%) of the title compound **8a**. MS (E^+) m/z : 178 (MH^+).


In a similar manner the following compounds were prepared.

Preparation	Structure
8b	
8c	
8d	

Preparation 9

5

4-(1-Isoquinolinyl)-2-aminothiazole 9a



Step 1

10 To a solution of 1-isoquinolinecarboxylic acid (11.55 mmol, 2.0 g) in THF (20.0 mL) and methanol (10.0 mL) is added trimethylsilyldiazomethane (69.3 mmol, 32.0 mL of a 2 M solution in hexanes). After 2 h at RT the reaction mixture was concentrated in vacuo to give 1.17 g (Y: 99%) of the product of step 1. MS (E+) *m/z*: 188 (MH⁺).


15

Step 2

To a solution of the product of step 1 (10.69 mmol, 2.0 g) in dichloromethane (100.0 mL) was added trimethylaluminum (32.88 mmol, 16.44 mL of a 2.0 M solution in toluene) at -78 °C. After the addition was complete the reaction was allowed to warm to 0 °C. The reaction mixture was then quenched with water (30 mL) and extracted with dichloromethane (3 x 30 mL). The organic phases were concentrated in vacuo and the residue chromatographed on silica gel (eluted with 10% ethyl acetate in hexanes) to give 930 mg (Y: 51%) of the product of step 2. MS (E+) m/z : 172 (MH⁺).

Step 3

The product of step 2 was converted to the title compound **9a** as described in preparation 8, step 2. MS (E+) m/z : 228 (MH⁺).

Preparation 105-(1-naphthyl)-2-aminopyridine 10a

Potassium carbonate (5.19 mmol, 717 mg) in water (2.5 mL) and tetrakis(triphenylphosphine)palladium(0) (0.04 mol%, 80 mg) in ethyl alcohol (2.5 mL) were added to 2-amino-5-bromopyridine (1.73 mmol, 299 mg) and 1-naphthaleneboronic acid (2.60 mmol, 446 mg) in benzene (10.0 mL). After 2 hours at 90 °C the reaction mixture was quenched with water (30 mL) and extracted with dichloromethane (3 x 30 mL). The organic phases were concentrated in vacuo and the residue chromatographed on silica gel (eluted with 50% ethyl acetate in hexanes) to give 260 mg (Y: 68%) of the title compound **10a**. MS (E+) m/z : 381 (MH⁺).


In a similar manner the following compounds were prepared.

Preparation	Structure
10b	
10c	

5

Preparation 11a

4-(2,3-Dihydro-benzo[1,4]dioxin-5-yl)-thiazol-2-ylamine



10 Step 1

A suspension of 2,3-dihydroxy-benzoic acid methyl ester (336 mg, 2 mmol) and cesium carbonate (1.56 g, 4.8 mmol) in DMF was stirred at room temperature for 0.5 h. 1,2-Dibromoethane (0.224 ml, 2.6 mmol) was added to the DMF solution. The mixture was stirred at 80 C for 4 h, and then diluted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO₄, filtered and concentrated in vacuo to give the crude product. It was chromatographed on silica gel with EtOAc/hexane (20% - 40%) as eluent to afford 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid methyl ester as a white solid. (223 mg, 1.14 mmol, 57.4% yield).

20

Step 2

Reference: *Tetrahedron Lett*, 1997, 3173-78

To a mixture of 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid methyl ester (100 mg, 0.515 mmol) and chloriodomethane (0.075 ml, 1.03 mmol) in 1 ml of THF was added a solution of LDA in THF (2M, 0.57 ml, 1.13 mmol) dropwise at -78 C over 15 min. The reaction mixture was stirred at -78 C for 10 min. A solution of acetic acid (0.75 ml) in THF (5 ml) was added dropwise over 5 min at -78 C. The resulting solution was stirred at the same temperature for additional 10 min. and was then partitioned between ethyl acetate and water. The organic layer was washed with aqueous sodium bicarbonate, brine, dried over MgSO₄ and concentrated in vacuo to give the crude 2-chloro-1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-ethanone as a light brown liquid.

Step 3

The crude product of step 2 was dissolved in EtOH (1.5 ml). Thiourea (76 mg, 1 mmol) was added followed by addition of TEA (0.14 ml, 1 mmol). The solution was heated at 80 C for 6 h. After removal of ethanol, the reaction mixture was taken into ethyl acetate and aqueous sodium bicarbonate. The organic layer was washed with 0.5 N HCl. After separation, the aqueous layer was adjusted to pH 9 with sodium carbonate, and extracted with ethyl acetate. The ethyl acetate solution was washed with brine, dried over MgSO₄ and concentrated to give 4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-thiazol-2-ylamine 11a as a brown solid, 37 mg (0.16 mmol, 31 % yield). ¹H NMR (CDCl₃) δ 7.46 (dd, 1H), 7.04 (s, 1H), 6.75-6.83 (m, 2H), 5.33 (br s, 2H), 4.23-4.34 (m, 4H); LC/MS m/z 235 (M+H)⁺.


25

Preparation 11b4-Benzo[1,3]dioxol-4-yl-thiazol-2-ylamine

Preparation 11b was prepared in a similar manner to preparation 11a.

Compound	Structure
11b	

5

Preparation 12a10 Step 1

To 1,3-dimethyl-4,6-dinitrobenzene (5.0 g, 25.489 mmol) under nitrogen in 50.0 mL DMF was added 10.16 mL N,N-dimethylformamide dimethyl acetal (76.468 mmol, 9.112g, 3.0 eq). The mixture was stirred under nitrogen at 140°C for 5 h, allowed to cool to room temperature and the solvent was removed under vacuum to afford a dark, black solid. To this solid was added 330 mL of 50% aqueous THF, followed by sodium periodate (32.7g, 152.9 mmol, 6 eq). The solution turned red and produced a slight exotherm. The mixture was allowed to stir at room temperature for 5 h. This mixture was then filtered through a scintered glass funnel to remove excess solid material and rinsed with ethyl acetate until colorless. (Total volume of eluent

15

was 750 mL after rinsing). The filtrate was washed with 100 mL saturated $\text{NaHCO}_{3(\text{aq})}$. The aqueous was extracted again with 200 mL ethyl acetate. The organic layers were combined and dried over sodium sulfate. The solution was concentrated under vacuum. The remaining crude oil was chromatographed using silica gel eluted with 30% ethyl acetate in hexanes to yield 2.77 g of the product of step 1 as a yellow solid (48%).

Step 2

The product of step 1 (1.93 g, 8.62 mmol) and powdered iron (3.85 g, 68.93 mmol, 8 eq) were placed into a flask containing 100 mL of a 2:2:1 mixture of ethanol/acetic acid/water, respectively. The flask was placed into a 0°C ice bath and allowed to equilibrate for 20 minutes. 8 drops of concentrated HCl were added. The reaction began to change color (yellow to green to red/brown). After 1 hour, the cooling bath was removed and allowed to warm to room temperature. After stirring for an additional 1 hour at room temperature, the mixture was filtered through a thin pad of celite. The filtrate was concentrated under vacuum to afford a yellow/green solid. This crude material was chromatographed using silica gel eluted with 30% hexanes in ethyl acetate. Removal of the solvent under vacuum yielded 1.165 g of the product of step 2 as a yellow/orange solid (82%).

Step 3

To the product of step 2 (901 mg, 5.49 mmol) under nitrogen in 30.0 mL ethanol was added 0.92 mL pyruvic acid (1.160 g, 13.173 mmol) followed by 13.0 mL of 2N aqueous sodium hydroxide. The mixture was stirred at 80°C for 5 hours. 0.6 N Aqueous ammonia (~100 mL) was added and the mixture was gently heated to 74°C. A 0.6N HCl/0.3N AcOH solution was added until pH was ~ 4 to precipitate the product. The mixture was filtered to collect solid which was dried under vacuum to obtain 1.303 g of the product of step 3 as a yellow solid (88%).

Step 4


The product of step 3 (99 mg, 0.369 mmol) and ~3 mg Cu₂O (~ 0.018 mmol, 0.05 eq) were placed under nitrogen in 3.0 mL di(ethylene glycol) methyl ether. The mixture was stirred at 165°C for 6 h and ~30 mL concentrated aqueous ammonia was added. The mixture was extracted with 2 x 100 mL methylene chloride and dried over sodium sulfate, concentrated under vacuum and chromatographed using silica gel eluted with 1% triethylamine, 7% methanol in chloroform. The eluent was removed under vacuum to obtain 44 mg of the product of step 4 as a brown crystalline solid (67%) M+H=181.28.

10

Step 5

The product of step 4 (21 mg, 0.117 mmol), 49 µL methyl acrylic acid (50 mg, 0.583 mmol, 5 eq), and ~3 mg hydroquinone were placed in a tube under nitrogen in 1.0 mL xylenes. The tube was sealed with a teflon lined cap and heated at 140°C for 3 days. LC/MS shows reaction is complete. The solvent was removed under vacuum and the crude material was chromatographed using silica gel eluted with 1% triethylamine, 10% methanol in chloroform to afford 21 mg of the title compound 12a as a clear oil (68%). M+H=267.14

20

Preparation 13


Step 1

The product of preparation 12a, step 4 (128 mg, 0.710 mmol), ethyl methacrylate (442 μ L, 3.551 mmol, 5 eq), and ~ 20 mg hydroquinone into 5.0 mL xylenes were placed in a tube under nitrogen. The tube was sealed with a teflon lined cap and stirred at 140°C for 3 days. Solvent was removed under vacuum and the crude material was directly purified on prep HPLC. The retention times on the HPLC (both analytical and prep) for the two isomeric products are very similar. 24 mgs of the pure minor isomer and 28 mg of a mixture of both the major and minor isomers was isolated.

Step 2

The minor product of step 1 (24 mg, 0.082 mmol) was placed under nitrogen in 1.5 mL methanol. 0.3 mL of 1N NaOH were added and the mixture stirred at 60°C for 2 hours. An additional 0.1 mL of saturated aqueous NaOH were added and the mixture stirred an additional 5 h at 60°C. The mixture was allowed to cool, then 50 μ L TFA were added. The mixture was purified directly on prep HPLC. Solvent was removed under vacuum to afford 21 mg of the title compound 13 as a clear oil (~95%). M+H=267

20

Preparation 14

Step 1


Reference: B. Bacle and G. Levesque, *Polymer Communications*, 28, 36 (1987).

A 1L flask was charged with anthracene (14g, 0.078 mol, 1.0 equi.),
 5 hydroquinone (0.8g, 0.008 mol, 0.1 equi.), methacrylic acid (14 mL, 0.156 mol, 2.0
 equi.) and xylene (500 mL). The solution was heated to reflux for 1 day. The
 solution was cooled and concentrated *in vacuo*. The residue was dissolved in ethyl
 acetate and extracted with 1N NaOH (3x). The aqueous phase was acidified with 1N
 HCl, and the product was extracted with ethyl acetate (3x). The combined organic
 10 phases were concentrated *in vacuo* to give the crude product mixture.
 Recrystallization with hexane and ethyl acetate to yield 8g (40%) of the product of
 step 1, **14**: LC/MS (m/z 263 ($M-H$)⁺); ¹H NMR ($CDCl_3$) δ 7.08-7.25 (m, 8H), 4.37 (s,
 1H), 4.25(t, 1H), 2.61 (dd, 1H), 1.39 (dd, 1H), 1.07 (s, 3H).

15 Step 2


The product of step 1, **14** was resolved into its corresponding enantiomers,
14(R) and **14(S)** by chiral preparative HPLC with the following conditions, Column:
 Chiracel®-OJ, 5 X 50 cm, Mobile phase: trifluoroacetic acid/acetonitrile: 1/1000
 (vol/vol), Temperature: ambient, Flowrate: 70 mL/min, Injection: 1.5 grams in 50 mL
 20 solvent, Detection: UV (250 nm). Retention times for R-enantiomer, 30 min, S-
 enantiomer, 52 min. Analytical HPLC conditions, Column: Chiracel®-OJ, 4.6 X 250
 cm, Mobile phase: trifluoroacetic acid/acetonitrile: 1/1000 (vol/vol), Temperature:
 ambient, Flowrate: 1.5 mL/min, Detection: UV (250 nm). Retention times: R-
 enantiomer, 6.5 min, S-enantiomer, 15 min.

25

Preparation 15

Acrylic acid and anthracene were reacted as described in preparation 14 to provide compound 15.

5

Preparation 16a

To a solution of the product of step1 preparation 14 (5.0g, 18.9 mmol, 1.0
 10 equi.) in dichloromethane (20 mL) was added an oxalyl chloride solution in
 dichloromethane (2M, 11.4 mL, 22.8 mmol, 1.2 equi.) dropwise. The solution was
 stirred at RT for 2 hours, after which the solvent was removed *in vacuo*. The residue
 was dissolved in acetonitrile (20 mL) and added dropwise to a solution of ethylene
 glycol (1.27 mL, 22.8 mmol, 1.2 equi.) in acetonitrile (20 mL). The reaction solution
 15 was stirred at RT for 4 hours and then the solution was concentrated *in vacuo*.
 Purification by flash chromatography (10% ethyl acetate in hexane) yielded 2.0 g
 (34%) of compound 16a: ^1H NMR (CDCl_3) δ 7.52 (d, 1H), 7.09 – 7.27 (m, 8H), 4.40
 (s, 1H), 4.31 (t, 1H), 4.11(m, 1H), 4.0 (m, 1H), 3.63 (m, 2H), 2.72 (dd, 1H), 1.42 (dd,
 1H), 1.16(s, 3H).


20

In a similar manner the following compounds were prepared from the
 corresponding acids and alcohols.

Preparation Number	Chiral Compounds	Structure
16b		

Preparation Number	Chiral Compounds	Structure
16c		
16d		
16e	Chiral (S)	
16f	Chiral (R)	
16g	Chiral (S)	
16h	Chiral (R)	




Preparation 17



5

Reference: P.V. Alston, R.M. Ottenbrite, J. Newby, *J. Org. Chem.*, 44, 4939 (1979).

- 9-Anthracenecarboxylic acid (4 g, 0.017 mol, 1.0 equi.) was added to a mixture of methacrylic acid (20 mL, 0.23 mol, 14.0 equi.), benzene (20 mL) and hydroquinone (0.2 g, 0.0017 mol, 0.1 equi.). The solution was heated to reflux for 7 days. The solution was cooled and the precipitate formed was filtered and washed with benzene. The precipitate was recrystallized with hexane and ethyl acetate to yield 0.4 g (7.2%) of the ortho product 17a: MS (m/z 321(M-H)⁺); ¹H NMR (CDCl₃) δ 7.1–7.28 (m, 8H), 4.25 (t, 1H), 4.06 (s, 3H), 2.25 (dd, 1H), 1.69 (dd, 1H), 1.08 (s, 3H). The filtrate was extracted with 1N NaOH (3x). The aqueous phase was acidified with 1N HCl, and the product was extracted with ethyl acetate (3x). The organic phases were concentrated *in vacuo*. Recrystallization of the residue with hexane and ethyl acetate yielded 0.2 g (4%) of the meta product 17b MS (m/z 321 (M-H)⁺); ¹H NMR (CDCl₃) δ 7.16-7.27 (m, 8H), 4.36 (s, 1H), 4.08 (s, 3H), 2.90 (d, 1H), 1.67 (d, 1H), 1.06 (s, 3H).
- In a similar manner the following compounds were prepared from methacrylic acid and the appropriate anthracene.

Preparation Number	Structure
17C	
17D	
17E	


Preparation Number	Structure
17F	
17G	
17H	
17I	
17J	

EXAMPLES

The following Examples represent preferred embodiments of the invention.

EXAMPLE 1

5


















To a solution of the product of Preparation 14, step 1 (20 mg, 0.075 mmol, 1.0
equi.) in acetonitrile (2 mL) was added 1-[3-(dimethylamino) propyl]-3-
10 ethylcarbodiimide hydrochloride (DEC) (17 mg, 0.09 mmol, 1.2 equi.), 1-hydroxy-7-
azabenzotriazole (HOAt) (12 mg, 0.09 mmol, 1.2 equi.), triethyl amine (0.025 mL,
0.18 mmol, 2.5 equi.), and 2-amino-4,5-dimethylthiazole hydrochloride salt (14.8 mg,
0.09 mmol, 1.2 equi.). The reaction solution was heated to 80°C for 18 hours. The
reaction was then concentrated *in vacuo*. The product mixture was purified by flash
15 chromatography (20% ethyl acetate in hexane) to yield 19.8 mg (70%) of Example 1.
LC/MS (m/z 375, (M+H)+).







EXAMPLES 2 TO 339








In a similar manner Examples 2-339 were prepared from the coupling of the
20 appropriate acids and amines. Preparations of amines or acids not commercially
available are described in the preceding preparations section of this document. All
examples in the tables are racemic unless specified otherwise. Examples in the table
where one enantiomer predominates or is the sole component, are designated as either
R or S.








25









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
2			513.6
3			409.5
4			414.5
5			475.5
6			364.5
7			482.6
8			443.6

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
9			382.5
10			524.6
11			422.5
12			410.5
13			395.5
14			446.6
15			426.5
16			393.5









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
17			499.6
18			482.6
19			400.4
20			379.5
21			461.5
22			350.4








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
23			429.5
24			367.5
25			368.4
26			408.5
27			396.5
28			381.5
29			403.5








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
30			412.5
31			418.4
32			409.5
33			484.4
34			395.46
35			359.5
36			396.5








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
37			426.5
38			354.5
39			374.9
40-41			354.5
42			354.5
43			475.6
44			393.5
45			372.4

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
46			390.5
47			393.5
48			395.5
49			380.9
50			415.5
51			425.5
52			402.5
53			374.4








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
54			400.5
55			368.5
56			393.5
57			357.5
58			
59			369.5
60			369.5
61			383.5

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
62			399.5
63			399.5
64			422.4
65			422.4
66			413.5
67			409.5
68			329.4









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
69			360.5
70			432.5
71			397.5
72			370.5
73			446.6
74			368.5
75			383.5









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
76			354.5
77-78			354.5
79			390.5
80			357.5
81			390.5
82			446.6
83			373.5









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
84			383.5
85			343.4
86			360.5
87			437.6
88			390.5
89			374.4
90			369.5









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
91			422.4
92			383.5
93			383.5
94			427.5
95			399.5
96			399.5
97			396.5









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
98			413.5
99			413.5
100			399.5
101			379.47
102			329.41
103			461.5
104			422.6








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
105			457
106			402.6
107			481.5
108			458.5
109			432.5
110			436.6
111			485
112			472.6







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
113			481.6
114			410.5
115			424.6
116			431
117			426.5
118			410.5
119			341.4
120			414.5








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
121			396.5
122			450.6
123-124			341.4
125			385.4
126			354.5
127			431
128			486.52
129			441.51








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
130			402.56
131	Chiral (R)		472.61
132	Chiral (S)		472.61
133			344.4
134			345.4
135			354.5
136			357.5
137			358.4








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
138			381.4
139			385.4
140			386.5
141			395.5
142			401.5
143			403.5
144			403.5
145			405.5









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
146			405.5
147			409.5
148			469.6
149			472.6
150			497.5
151			422.55
152			458.59








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
153			472.61
154			466.59
155			490.6
156			456.55
157			478.64
158			386.5

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
159			389.5
160			389.5
161			417.6
162			403.5
163			417.6
164			432.57
165			417.6

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
166			417.6
167			391.5
168			423.5
169			431.6
170			390.5
171			397.5
172			486.64








Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
173			455.56
174			466.59
175			452.58
176			502.64
177			462.57
178			502.64
179			440.5









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
180			440.5
181			467.6
182			436.6
183			455.6
184			440.5
185			457
186			457
187			467.6









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
188	Chiral (R)		486.64
189	Chiral (S)		486.64
190			467.58
191			526.7
192			498.7
193			510.7
194			490.6

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
195			541.7
196			436.6
197			466.6
198			541.7
199			454.6
200			476.6
201			534.7
202			459.6







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
203			462.6
204			469.59
205			405.5
206			502.64
207	Chiral (R)		490.6
208	Chiral (S)		490.6
209			464.63
210			385.51







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
211			493.68
212			551.51
213	Chiral (S)		502.64
214	Chiral (R)		502.64
215			473.55
216	Chiral (S)		455.56
217	Chiral (R)		455.56







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
218	Chiral (S)		469.59
219	Chiral (R)		469.59
220			423.54
221			548.45
222			423.54
223			548.45
224			423.54
225			598.51









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
226			485.59
227	Chiral (S)		485.59
228	Chiral (R)		485.59
229	Chiral (S)		473.55
230	Chiral (R)		473.55
231			522.67
232	Chiral (S)		522.67
233	Chiral (R)		551.51










Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
234	Chiral (S)		551.51
235	Chiral (S)		598.51
236	Chiral (R)		598.51
237			473.6
238			473.6
239	Chiral (S)		417.56
240			500.62

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
241			530.65
242			522.67
243	Chiral (S)		522.67
244			530.65
245			517.61
246			517.61









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
247			497.62
248			500.62
249			544.68
250			511.65
251			531.64
252			531.64









Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
253			514.65
254			492.58
255			480.59
256			478.64
257			466.56
258			348.43

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
259			492.58
260			511.65
261			497.62
262			535.6
263			515.61
264	Chiral (S)		396.5
265	Chiral (S)		426.5
266	Chiral (S)		354.5










Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
267	Chiral (S)		374.5
268	Chiral (S)		380.9
269	Chiral (S)		329.4
270	Chiral (S)		343.4
271	Chiral (S)		360.5
272	Chiral (S)		329.4
273	Chiral (S)		422.6
274	Chiral (S)		457
275	Chiral (S)		458.5










Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
276	Chiral (S)		432.5
277	Chiral (S)		436.6
278	Chiral (S)		410.5
279	Chiral (S)		424.6
280	Chiral (S)		431
281	Chiral (S)		426.5
282	Chiral (S)		410.5
283	Chiral (S)		414.5
284	Chiral (S)		396.5

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
285	Chiral (S)		431
286	Chiral (S)		441.5
287	Chiral (S)		472.6
288	Chiral (S)		417.6
289	Chiral (S)		440.5
290	Chiral (S)		436.6
291	Chiral (S)		440.5
292	Chiral (S)		457




Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
293	Chiral (S)		467.6
294	Chiral (S)		454.6
295	Chiral (S)		476.6
296	Chiral (S)		459.6
297	Chiral (S)		427.5
298	Chiral (S)		423.5
299-300	Chiral (S)		462.6
301	Chiral (S)		359.5


Example	Chiral Compounds	Structure	MS: (M+H \approx MW +1)
302	Chiral (S)		422.4
303	Chiral (R)		396.5
304	Chiral (R)		426.5
305	Chiral (R)		354.5
306	Chiral (R)		374.5
307	Chiral (R)		380.9
308	Chiral (R)		329.4
309	Chiral (R)		343.4

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
310	Chiral (R)		360.5
311	Chiral (R)		329.4
312	Chiral (R)		422.6
313	Chiral (R)		457
314	Chiral (R)		458.5
315	Chiral (R)		432.5
316	Chiral (R)		436.6
317	Chiral (R)		410.5
318	Chiral (R)		424.6

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
319	Chiral (R)		431
320	Chiral (R)		426.5
321	Chiral (R)		410.5
322	Chiral (R)		414.5
323	Chiral (R)		396.5
324	Chiral (R)		431
325	Chiral (R)		441.5
326	Chiral (R)		472.6
327	Chiral (R)		417.6

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
328	Chiral (R)		440.5
329	Chiral (R)		436.6
330	Chiral (R)		440.5
331	Chiral (R)		457
332	Chiral (R)		467.6
333	Chiral (R)		454.6
334	Chiral (R)		476.6
335	Chiral (R)		459.6
336	Chiral (R)		427.5

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
337	Chiral (R)		423.5
338	Chiral (R)		359.5
339	Chiral (R)		422.4

EXAMPLE 340

5

Step 1

To a solution of the product of preparation 14 (100 mg, 0.38 mmol, 1.0 equi.) in acetonitrile (5 mL) was added 1-[3-(dimethylamino) propyl]-3-ethylcarbodiimide hydrochloride (DEC) (87 mg, 0.45 mmol, 1.2 equi.), 1-hydroxy-7-azabenzotriazole (HOAt) (62 mg, 0.45 mmol, 1.2 equi.), triethyl amine (0.13 mL, 0.94 mmol, 2.5 equi.), and 2-aminothiazole (45.5 mg, 0.45 mmol, 1.2 equi.). The reaction solution was heated to 80°C for 18 hours. The reaction was then concentrated *in vacuo*. The product mixture was purified by flash chromatography (20% ethyl acetate in hexane) to yield 112.4 mg (86%) of the product of step 1: LC/MS (*m/z* 347, (M+H)⁺); ¹H NMR (CDCl₃) δ 7.52 (d, 1H), 6.98 – 7.27 (m, 9H), 4.42 (s, 1H), 4.32 (t, 1H), 2.69 (dd, 1H), 1.52 (dd, 1H), 1.16(s, 3H).




15


Step 2

To a solution of the product of step 1 (175 mg, 0.5 mmol, 1.0 equi.) in THF (5 mL) was added sodium hydride (18 mg, 0.75 mmol, 1.5 equi.) and the solution stirred at RT for 1 hour. A solution of methyl iodide (0.047 mL, 0.75 mmol, 1.5 equi.) in THF (1 mL) was added and the reaction solution was stirred at RT for 3 hours. The solution was quenched with ethyl acetate. The organic layer was washed with water, saturated sodium chloride, dried with magnesium sulfate and concentrated *in vacuo*. Purification of the crude product mixture by flash chromatography (10% ethyl acetate in hexane) yielded 141.7 mg (78%) of **Example 340**: LC/MS (m/z 361 ($M+H$)⁺); ¹H NMR (CDCl₃) δ 6.41-7.12 (m, 8H), 4.67 (s, 1H), 4.3 (t, 1H), 3.63 (s, 3H), 3.0 (dd, 1H), 1.49 (dd, 1H), 1.07 (s, 3H).

EXAMPLES 341 TO 343

In a similar manner the following compounds were prepared.

Example	Structure	MS: ($M+H = MW + 1$)
341		436.58
342		486.64
343		562.74

EXAMPLES 344 TO 3465 Step 1

To a solution of the product of Preparation 14, (4.72 mmol, 1.25 g) in acetonitrile (20 mL) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI), (5.66 mmol, 1.09 g), 1-hydroxy-7-azabenzotriazole (HOAt), (5.66 mmol, 0.77 g), triethylamine (11.8 mmol, 1.20 g) and the product of preparation 11 (5.66 mmol, 1.41 g). The resulting mixture was heated to 80 °C for 20 h, cooled and concentrated in vacuo. The residue was chromatographed on silica gel (eluted with 15% ethyl acetate in hexane) to give 1.80 g (Y: 77%) of Example 344. MS (E+) m/z : 494 (MH⁺).

15 Step 2



To a solution of Example 344 (3.44 mmol, 1.70 g) in EtOH (30 mL) was added 10 N NaOH (2.0 mL). The resulting mixture was heated to 75 °C for 2.5 h, cooled and diluted with an excess of 1 N HCl. The mixture was then extracted with dichloromethane (3 x 100 mL), dried over Na₂SO₄ and concentrated under vacuo to give 1.40 g (Y: 88%) of Example 345. MS (E+) m/z : 467 (MH⁺).







Step 3








To a solution of Example 345 (0.038 mmol, 18.0 mg) in tetrahydrofuran (1.0 mL) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI), (0.046 mmol, 8.9 mg), 1-hydroxy-7-azabenzotriazole (HOAt), (0.046 mmol, 6.3 mg), triethylamine (0.046 mmol, 5.6 mg) and aniline (0.046 mmol, 4.3 mg). After 20 h at room temperature the product was purified using solid phase extraction cartridges (500 mg 1/1 high load, SCX strong cation exchanger/SAX strong anion exchanger) from United Chemical Technologies, Inc. After conditioning the cartridge with MeOH (2 x 1.5 mL) the crude reaction mixture was loaded on to the cartridge. The cartridge was then washed with MeOH (2 x 1.5 mL) to afford two fractions of the title compound. These fractions were combined & concentrated and then purified a second time using solid phase extraction cartridges (500 mg SAX strong anion exchanger) to remove any HOAt that was still present. After conditioning the cartridge with MeOH (2 x 1.5 mL) the crude product was loaded on to the cartridge. The cartridge was then washed with MeOH (1 x 1.5 mL) and the eluent was collected. The resultant eluent was evaporated *in vacuo* to afford 7.70 mg (37%) of Example 346. MS (E+) *m/z*: 542 (MH⁺).







EXAMPLES 347 TO 563







20 In a similar manner the Examples 347-563 were prepared.







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
347			555.7
348			555.7

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
349			569.73
350			493.6
351			547.7
352			561.8
353			571.7
354			571.7






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
355			571.7
356			590.2
357			585.7
358			585.7
359			590.2
360			585.7
361			523.7







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
362			569.7
363			604.2
364			599.8
365			599.8
366			604.2
367			599.8







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
368			590.2
369			604.2
370			617.8
371			583.8
372			523.7
373			519.7






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
374			535.7
375			535.7
376			581.7
377			555.7
378			576.7
379			599.8







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
380			626.8
381			583.8
382			638.6
383			629.8
384			559.7
385			652.6







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
386			551.7
387			613.8
388			597.8
389			597.8
390			627.8







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
391			601.7
392			533.7
393			575.8
394			561.8
395			561.8
396			545.7

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
397			591.7
398			549.7
399			561.7
400			570.7
401			542.7
402			542.7







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
403			556.7
404			536.7
405			570.7
406			610.8
407			548.7







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
408			624.8
409			550.7
410			570.7
411			584.7
412			562.7
413			559.7







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
414			493.6
415			547.7
416			561.8
417			541.7
418			571.7
419			571.7

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
420			571.7
421			590.2
422			585.7
423			585.7
424			590.2
425			585.7






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
426			523.7
427			569.7
428			604.2
429			599.8
430			599.8
431			604.2







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
432			599.8
433			590.2
434			604.2
435			617.8
436			583.8
437			523.7







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
438			535.7
439			581.7
440			555.7
441			576.7
442			608.8
443			599.8







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
444			569.7
445			561.7
446			583.8
447			638.6
448			629.8
449			559.7






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
450			652.6
451			652.6
452			551.7
453			601.7
454			597.8
455			597.8






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
456			627.8
457			601.7
458			533.7
459			575.8
460			561.8






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
461			561.8
462			545.7
463			549.7
464			626.8
465			570.7
466			542.7






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
467			556.7
468			556.7
469			536.7
470			570.7
471			610.8
472			548.7







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
473			624.8
474			550.7
475			562.7
476			559.7
477			481.58
478			467.55







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
479			572.69
480			572.69
481			602.72
482			606.1
483			587.7






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
484			589.7
485			631.8
486			601.7
487			601.7
488			585.7






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
496	Chiral (S)		589.7
497	Chiral (S)		631.8
498	Chiral (S)		601.7
499	Chiral (S)		601.7
500	Chiral (S)		585.7






Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
501			576.1
502			591.7
503			576.1
504			576.1
505			610.6

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
506			610.6
507			617.8
508			610.6
509			610.6
510			581.7
511			548.7







Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
512			677.7
513			549.7
514			542.7
515			582.7
516			617.7
517			563.7

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
523			585.7
524			573.7
525			585.7
526			587.8
527			609.7




Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
528			555.7
529			569.7
530			587.8
531			562.7
532			565.7


Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
533			606.1
534			545.7
535			572.7
536	Chiral (S)		466.56
537	Chiral (S)		480.59

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
538	Chiral (S)		572.7
539	Chiral (S)		587.8
540	Chiral (S)		585.7
541	Chiral (S)		573.7
542	Chiral (S)		585.7

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
543	Chiral (S)		582.7
544	Chiral (S)		576.1
545	Chiral (S)		571.7
546	Chiral (S)		533.7
547	Chiral (S)		542.7
548	Chiral (S)		582.7

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
555	Chiral (R)		585.7
556	Chiral (R)		573.7
557	Chiral (R)		585.7
558	Chiral (R)		582.7
559	Chiral (R)		576.1
560	Chiral (R)		571.7

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
561	Chiral (R)		533.7
562	Chiral (R)		542.7
563	Chiral (R)		582.7

EXAMPLE 564

Step 1

From the frozen vegetative stock culture of *Streptomyces griseus* ATCC 10137, 2 ml was used to inoculate 100 ml of F7 medium contained the following per liter of deionized water: dextrose, 10 g; yeast extract, 10 g; malt extract, 10 g; peptone, 1 g, in a 500 ml flask (pH was adjusted to 7 before sterilization at 120°C for 30 minutes). The culture was incubated for 3 days at 28°C on a rotary shaker operating at 250 rpm. Two ml of this culture was used to inoculate each of twelve 500-ml flasks containing 100 ml of F7 medium. The flasks were incubated at 28°C on a rotary shaker operating at 250 rpm for 17 hours. Eight mg of Preparation 16g S-isomer (97.9%ee) in 0.32 ml DMF was added to each flask. The flasks were then returned to the shaker and incubated for additional 9.5 hours at 28°C and 250 rpm. The culture was pooled and subjected to sonication for total of 5 min. with a High Intensity Ultrasonic Processor (Model: VCX600, Sonics & Material Inc.) equipped with a microtip, at 40% out put. The resulting mixture was extracted with 600 ml ethyl acetate and the ethyl acetate extract was evaporated to dryness. The residue was dissolved in 2 ml of acetonitrile and subjected to preparative HPLC with a YMC ODS-A column (30mm ID X 100 mm length, 5µ particle size). Elution flow rate was 30 ml/min. In each run, sample (0.5 to 1 ml) was loaded onto the column at water (solvent A)-acetonitrile (solvent B) 90/10 v/v and separated using the following gradient program: 10% B, 3 min; 10% to 35% B linear gradient, 1 min; 35% B, 9 min; 35 % to 60% B linear gradient, 1 min; 60 % B, 4 min; 60 % to 90% B linear gradient, 1 min; 90 % B, 4 min. Detection (UV) was at 210 nm. The fractions containing BMS-585157 was eluted between 18 to 19 minutes. The BMS-585157 fractions were pooled and evaporated *in vacuo* to a small volume, then was lyophilized. A total of 60 mg of BMS-585751 was obtained as light yellow solid (yield, 62.5%). The reaction and purification were monitored by analytical HPLC with a Hewlett Packard 1100 Series Liquid Chromatograph using an YMC Packed ODS-AQ column, 4.6 mm i.d. x 15 cm l. A gradient system of 1 mM HCl in water (solvent A) and acetonitrile (solvent B) was used: 70% to 90%B linear gradient, 5 min; 90%B, 1.5 min; 90% to 70% linear gradient, 0.5 min. The flow rate was 1.2 ml/min and UV detection was at 210 nm. Retention time for starting compound and product was 5.16 and 2.76 min,


respectively. ¹H-NMR Observed Chemical Shifts (relative to CD₃CN signal δ 1.94): δ 7.33 (3H, m), 7.21 (1H, m), 7.15 (2H, m), 7.09 (2H, m), 4.61 (1H, dd, J₁ = 5.8 Hz, J₂ = 3.2 Hz, CH-3), 4.40 (1H, s, CH-11), 4.32 (1H, d, J = 3.5 Hz, CH-4), 3.51 (3H, s, CH₃-19), 2.90 (1H, d, J = 6.0 Hz, OH), 0.93 (1H, s, CH₃-18). ¹H-¹H NOE Observed
5 NOE: CH-4 and OH (when CH-3 was irradiated); CH-11 and OH (when CH₃-18 was irradiated). MS: +c APCI (m/z): 312 ([M+H₂O]⁺), 294, 277.

Step 2

To a solution of the product of step 1 (0.079 mmol, 23 mg) in MeOH (2 mL)
10 was added sodium hydroxide (400 µL of 1 N NaOH, 0.4 mmol). After 4 hours at 75 °C and 16 hours at RT the reaction mixture was quenched with 1N HCl (3 mL) and extracted with dichloromethane (3 x 30 mL). The organic phases were dried over Na₂SO₄ and concentrated in vacuo to give 19.6 g (Y: 89%) of the product of step 2.

Step 3

To a solution of the product of step 2 (0.070 mmol, 19.6 mg) in acetonitrile (1.0 mL) was added 1-[3-(dimethylamino)propyl-3-ethylcarbodiimide hydrochloride (EDCI), (0.084 mmol, 16 mg), 1-hydroxy-7-azabenzotriazole (HOAt), (0.084 mmol, 11.5 mg), triethylamine (0.175 mmol, 17.7 mg) and Preparation 1a (0.086 mmol, 21
20 mg). The resulting mixture was heated to 80 °C for 20 h, cooled and diluted with MeOH (1.0 mL). The diluted reaction mixture was then purified by preparative HPLC to afford the TFA salt of the title compound. The product was then neutralized using a solid phase extraction cartridge (500 mg high load, SCX strong cation exchanger from United Chemical Technologies, Inc). After conditioning the
25 cartridge with MeOH (2 x 1.5 mL) the product was loaded on to the cartridge. The cartridge was then washed with MeOH (2 x 1.5 mL), followed by a 2N NH₃ in MeOH solution to afford 18.8 mg (55%) of Example 564. MS (E+) m/z: 507 (MH⁺).


EXAMPLE 565

- 5 To a solution of Example 178 (20.0 mg, 0.04 mmol, 1.0 equi.) in dichloromethane (5 mL) at 0°C, was added a solution of boron tribromide in dichloromethane (1M, 0.20 mL, 0.20 mmol, 5 equi.). The reaction solution was stirred at 0°C for 3 hours, and let warmed up to room temperature and let stirred at room temperature overnight. The next day, the reaction solution was quenched with
- 10 methanol in an ice bath. The crude product mixture was purified by reversed phased PREP HPLC, followed by neutralization with cation exchange SPE, to yield 5.4 mg (28% yield) of Example 565: LC/MS (m/z 489, (M+H)⁺).

EXAMPLES 566 TO 567

- 15 Examples 566 to 567 in the table below were prepared in a similar manner from the corresponding methyl ethers.

Example	Structure	MS: (M+H = MW +1)
566		488.61
567		488.61

EXAMPLES 568 TO 5695 Step 1

To a solution of the product of preparation **16d** (2.45 mmol, 650 mg) in THF (10.0 mL) at -78°C was added lithium diisopropylamide (2.94 mmol, 1.47 ml of a 2 M solution in heptane/THF/ethyl benzene) dropwise. After 1 hour, bromoacetonitrile (3.68 mmol, 440 mg) in THF (0.70 mL) was added dropwise. The mixture was

10 allowed to warm to RT. After 16 hours the reaction mixture was quenched with 1N HCl (30 mL) and extracted with dichloromethane (3 x 30 mL). The organic phases were concentrated in vacuo and the residue chromatographed on silica gel (eluted with 20% ethyl acetate in hexane) to give 510 mg (Y: 69%) of the product of step 1.

15 Step 2

To a solution of the product of step 1 (1.68 mmol, 510 mg) in THF (3.4 mL) was added lithium hydroxide (1.7 mL of 5N LiOH). After 20 hours at 70°C the reaction mixture was quenched with 1N HCl (30 mL) and extracted with dichloromethane (3 x 30 mL). The organic phases were dried over Na_2SO_4 and

20 concentrated in vacuo to give 410 mg (Y: 84%) the product of step 2

Step 3



To a solution of the product of step 2 (0.45 mmol, 130 mg) in dichloromethane (2.0 mL) was added oxalyl chloride (0.54 mmol, 0.28 mL of a 2 N solution in dichloromethane) and DMF (2 drops). After 1 hour at RT the reaction mixture is concentrated in vacuo and then redissolved in dichloromethane (1.0 mL). To the resulting mixture is then added triethylamine (0.54 mmol, 0.075 mL) and methylamine (0.90 mmol, 0.45 mL of a 2 M solution in THF). After 2 hours the reaction mixture was quenched with saturated sodium bicarbonate solution, extracted by dichloromethane (3 x 30 mL), dried over Na₂SO₄ and concentrated under vacuo to give 53 mg (Y: 39%) of Example 568.


Step 4


To a solution of the product of step 3 (0.132 mmol, 40 mg) in methanolic ammonia (7.0 mL) was added 5% rhodium on alumina (100 mg). The reaction mixture was then allowed to hydrogenate at 55 psi of H₂ in a Parr apparatus. After 20 hours the reaction mixture was filtered through celite and concentrated in vacuo to give 40 mg (Y: 99%) of Example 569.

EXAMPLES 570 TO 572

In a similar manner the Examples 570 to 572 were prepared.

Example	Structure	MS: (M+H = MW +1)
570		291.4
571		360.48

Example	Structure	MS: (M+H = MW +1)
572		486.64

EXAMPLE 573

5

Step 1

To a solution of the product of preparation **16d** (3.90 mmol, 1.03 g) in THF (8.0 mL) and TMEDA (1.0 mL) at -78°C was added lithium diisopropylamide (4.69 mmol, 2.35 ml of a 2 M solution in heptane/THF/ethyl benzene) dropwise. After 1 hour the reaction mixture was saturated with ethylene oxide gas. The reaction mixture was then warmed to RT over 3 hours, quenched with 1N HCl (30 mL) and extracted with dichloromethane (3 x 30 mL). The organic phases were concentrated in vacuo and the residue chromatographed on silica gel (eluted with 10% ethyl acetate in hexane) to give 220 mg (Y: 22%) of the product of step 1.

15

Step 2


To a solution of the product of step 1 (0.471 mmol, 130 mg) in dichloromethane (8.0 mL) under nitrogen at 0°C was added trimethylaluminum (3.77 mmol, 1.88 ml of a 2 M solution in toluene). The reaction mixture was allowed to stir at 0°C for 20 min and then at RT for 1 h. 2-Aminothiazole (3.77 mmol, 377 mg) in dichloromethane (5.0 mL) was then added. After 16 hours at reflux the reaction mixture is quenched with 1N HCl (30 mL) and extracted with dichloromethane (3 x 30 mL). The organic phases were concentrated in vacuo and the residue

20

chromatographed on silica gel (eluted with 5% methanol in dichloromethane) to give 91 mg (Y: 51%) of Example 573. (E+) m/z : 376 (MH^+).

EXAMPLES 574 TO 575

5



Step 1

To a solution of Example 241 (80 mg, 0.15 mmol) in methanol (5 mL) was added a sodium hydroxide solution (1.0 mL) (solution is 1:1 of 50%NaOH and water). The reaction solution was heated to 60°C for 5 hours. The solution was cooled and quenched with HCl (6N). The product was extracted with ethyl acetate (3X). The combined organic extracts were dried with anhydrous magnesium sulfate and concentrated *in vacuo* to give 68 mg (87% yield) of Example 574. LC/MS (m/z 517, ($M+H$)⁺).


Step 2


To a solution of the product of step 1 (20 mg, 0.038 mmol, 1.0 equi.) in acetonitrile (2 mL) was added 1-[3-(dimethylamino) propyl]-3-ethylcarbodiimide hydrochloride (DEC) (8.9 mg, 0.046 mmol, 1.2 equi.), 1-hydroxy-7-azabenzotriazole (HOAt) (6.3 mg, 0.046 mmol, 1.2 equi.), triethylamine (0.013 mL, 0.097 mmol, 2.5 equi.), and ethylamine (2.1 mg, 0.046 mmol, 1.2 equi.). The reaction solution was heated to 80°C for 18 hours and followed by concentrated *in vacuo*. The product mixture was purified by reversed phased PREP HPLC, followed by neutralization with cation exchange SPE, to yield 3.1 mg (14%) of Example 575 : LC/MS (m/z 544, (M+H)⁺); ¹H NMR (CDCl₃) δ 8.22 (m, 1H), 7.89(m, 2H), 7.60 (d, 1H), 7.14-7.53 (m, 11 H), 7.03 (s, 1H), 4.46 (s, 1H), 3.69 (q, 2H), 2.85 (d, 1H), 1.83 (d, 1H), 1.36 (t, 3H), 1.12 (s, 3H).

EXAMPLES 576 TO 578

In a similar manner the Examples 576 to 578 were prepared.

Example	Structure	MS: (M+H = MW +1)
576		581.7
577		598.77

Example	Structure	MS: (M+H = MW +1)
578		585.73

EXAMPLE 579


5

To a mixture of Example 240 (28 mg, 0.056 mmol, 1.0 equi.) and ethylamine (3.0 mg, 0.067 mmol, 1.2 equi.) in methanol (2 mL, 1.0 % acetic acid) was added sodium cyanoborohydride (3.5 mg, 0.056 mmol, 1.2 equi.). The solution was stirred at room temperature for 18 hours. The crude product mixture was purified by reversed


10 phase PREP HPLC, followed by neutralization with cation exchange SPE, to yield 3.8 mg (13%) of Example 579: LC/MS (m/z 530, (M+H)⁺); ¹H NMR (CDCl₃) δ 8.25 (m, 1H), 7.87 (m, 2H), 7.62 (d, 1H), 7.51 (m, 3H), 7.06-7.52 (m, 7H), 7.06 (s, 1H), 4.40 (s, 1H), 3.7 (s, 2H), 2.99 (q, 2H), 2.60 (d, 1H), 1.58 (d, 1H), 1.28 (t, 3H), 1.19 (s, 3H).

EXAMPLE 580


In a similar manner the Example 580 was prepared.

Example	Structure	MS: (M+H = MW +1)
580		571.75

5

EXAMPLE 581


Example 252 (25 mg, 0.05 mmol) was dissolved in a solution of ethanol (5
 10 mL) and hydrochloric acid (concentrated, 0.25 mL) at room temperature. Zinc dust
 (20 mg) was added in and the reaction solution was stirred at room temperature for 24
 hours. The reaction was quenched with sodium bicarbonate solution (10%) and ethyl
 acetate. The organic phase was washed with 1N sodium hydroxide solution, dried and
 concentrated *in vacuo* to give the crude product mixture. The product was purified by
 15 PREP HPLC, followed by cation exchange SPE to give 4.1 mg (16% yield) of
 Example 581 : MS (m/z 502 (M+H)⁺).

EXAMPLE 582

5 To a solution of Example 112 (33 mg, 0.070 mmol) in 1.50 mL anhydrous diethyl ether at room temperature was added 0.18 mL of a 1.0M solution of lithium aluminum hydride in THF (0.180 mmol, 2.6 eq). After stirring at room temperature for 3 h an additional 0.18 mL lithium aluminum hydride solution (0.180 mmol, 2.6 eq) was added to push the reaction further. The mixture was allowed to stir for 48 h at

10 rt, and quenched by adding 0.15 mL methanol dropwise, then 0.15 mL water, then 20 mL saturated aqueous KOH. Extracted 2 x 30 mL ethyl acetate. Dried over sodium sulfate. Concentrated under vacuum. Purified the crude material using prep HPLC. Free-based the product by passing through a basic SCX cartridge using methanol as the eluent. Removal of the solvent afforded 2.5 mg of Example 582 as a solid white

15 film (8%) LC/MS (m/z 459, $(M+H)^+$).

EXAMPLE 583

20

Step 1: 7-methoxy-2-methyl-quinolinyl-4-boronic acid

To a solution of 4-bromo-7-methoxy-2-methyl-quinoline (700 mg, 2.8 mmol), prepared according to a known procedure (Reference: Abe, Y. *et. al. J. Med. Chem.* 1998, 41, 4062-4097), in THF (15 mL) at -78°C were added triisopropyl borate (1.3

mL, 5.6 mmol) and *t*-butyllithium (1.7 M, 5.0 mL). The solution was then slowly warmed to room temperature and kept stirring overnight. Next morning, the solution was quenched with 1N HCl (1.5 mL) and the solid was thus obtained after decanting THF. The solid was dissolved in MeOH and diluted with CH₂Cl₂. The solution was
5 filtered and the filtrate was concentrated to provide 7-methoxy-2-methyl-quinolinyl-4-boronic acid (560 mg, 90%). MS (ESI) (M+1) = 218.26.


Step 2: 4-(5-bromo-2-nitro-1*H*-imidazol-4-yl)-7-methoxy-2-methyl-quinoline

To a solution of the boronic acid from Step 1 (560 mg, 2.6 mmol) and 4,5-
10 dibromo-2-nitro-1*H*-imidazole (380 mg, 1.4 mmol), prepared according to a known procedure (Reference: Palmer, B. D. *et. al. J. Chem. Soc. Perkin Trans I*, 1989, 95-99), in 50 mL of THF was added 20 mL of sat. K₂CO₃. To this solution was bubbled a flow of N₂ for 30 minutes and then 200 mg of tetrakis(triphenylphosphine)palladium(0) (0.17 mmol) was added. The solution was
15 heated at 80 °C overnight. After cooling down, the solution was diluted with EtOAc and the organic layer was separated and washed with brine. The organic layer was dried over MgSO₄. After filtration and concentration, the residue was purified by flash column chromatography to provide the desired 4-(5-bromo-2-nitro-1*H*-imidazol-4-yl)-7-methoxy-2-methyl-quinoline (114 mg, 15%). MS (ESI) (M+1) = 363.29, 365.29.

20

Step 3: 4-(7-methoxy-2-methyl-quinolin-4-yl)-1*H*-imidazole-2-ylamine

To a solution of the product of Step 2 (114 mg, 0.31 mmol) in 15 mL of MeOH was added 100 mg of 10% Pd/C and the solution was purged with H₂. The solution was then stirred under H₂ atmosphere overnight. After filtration and
25 concentration, the desired 4-(7-methoxy-2-methyl-quinolin-4-yl)-1*H*-imidazole-2-ylamine (90 mg, 87%) was obtained as a HBr salt. MS (ESI) (M+1) = 255.33.

Step 4


Following a similar procedure as described in Example 1, the coupling
 5 reaction of the product of Step 3 (32 mg, 0.095mmol), and the acid of Preparation 17E
 (39 mg, 0.12mmol) provided compound of Example 583 (26 mg, 50%). MS (ESI)
 (M+1) = 546.33.

EXAMPLES 584 TO 586

10 In a similar manner to the procedure of Example 583, Examples 584 to 586
 were prepared from acid of Preparation 17E and the appropriate 4-(quinolin-4-yl)-1H-
 imidazole-2-ylamine or 4-isoquinolin-5-yl-1H-imidazol-2-ylamine. The amines were
 prepared according to the procedures described in Steps 1 to 3 of Example 583, *i.e.*
 via the Pd-catalyzed coupling reaction of 4,5-dibromo-2-nitro-1H-imidazole and the
 15 boronic acid derived from corresponding bromo-quinoline or bromo-isoquinoline,
 followed by the hydrogenation reaction.

Example	Structure
584	
585	

Example	Structure
586	

EXAMPLE 587

5

A suspension Example 212 (50 mg, 0.091 mmol) and cuprous cyanide (10 mg, 0.11 mmol) in DMF (2 mL) was introduced into a dried heavy wall Pyrex tube, flushed with nitrogen and tightly sealed. The tube was placed in a microwave (Smith Workstation 300W from Magnetron @ 2.45 GHz) and heated to 200°C while stirring

10

for 2.25 h. After the tube had cool down to room temperature, the reaction mixture was diluted with dichloromethane, washed with saturated sodium bicarbonate, dried over magnesium sulfate, filtered and concentrated *in vacuo* to provide a brown oil.

Flash chromatography (Isco silica gel, 4 g column, 10% ethyl acetate/hexane) provided Example 587 as an off-white solid (25 mg, 55% yield):

15






¹H NMR (CDCl₃) δ 8.67 (bs, NH), 8.36 (d, 1H), 8.32 (d, 1H), 7.95 (d, 1H), 7.73 (t, 1H), 7.62 - 7.69 (m, 2H), 7.26 - 7.38 (m, 4H), 7.15 - 7.20 (m, 3H), 7.14 (s, 1H), 7.09 (t, 1H), 4.37 - 4.46 (m, 2H), 2.65 (dd, 1H), 1.65 (dd, 1H), 1.18 (s, 3H) ; HPLC *t_R* = 4.2 min.; LC/MS *m/z* 498 (M+H)⁺.







20







EXAMPLES 588 TO 645

In a similar manner as described in Example 1, Examples 588 to 645 were prepared from the coupling of corresponding acids and amines. Preparations of







amines or acids not commercially available are described in the preceding preparations section of this document. All examples in the table are racemic unless specified otherwise. Examples in the table where one enantiomer predominates or is the sole component, are designated as either R or S. Separation of the enantiomers on a chiral column employed procedures described in the preceding preparations section of this document.








Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
588			419.18
589			510.34
590			448.38
591			535.2
592			536.21







Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
593			460.38
594			487.46
595			528.32
596			501.3
597			549.28
598			496.16







Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
599			467.2
600			466.13
601		Chiral (R)	532.29
602		Chiral (S)	532.26
603		Chiral (R)	512.27
604		Chiral (S)	512.24







Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
605			372.09
606			392.04
607			498.24
608			519.27
609			486.07
610			486.06

Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
611			493.07
612			468.13
613			496.13
614			482.09
615		Chiral (R)	536.25
616		Chiral (S)	536.27


Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
617			493.01
618			565.03
619			465.05
620			469.05
621			424.33
622			521.05
623			501.09

Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
624			504.99
625			524.95
626			596
627			451.15
628			508.14
629			488.17

Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
630			548.03
631			551
632			515.18
633			504.13
634			651.11
635			484.17

Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
636			552
637			499.1
638			569
639			495.05
640			506.1
641		Chiral (S)	519.05

Example No.	Structure	Chiral Compounds	MS: (M+H= MW+1)
642		Chiral (R)	519.01
643			489.07
644			519.19
645			481.34

EXAMPLE 646

5




To a solution of Example 178 (100 mg, 0.29 mmol, 1.0 equi.) in acetonitrile (5 mL) was added N-iodosuccinimide (65 mg, 0.29 mg, 1.0 equi.). The solution was stirred at room temperature for 2 hours. The solution was quenched with saturated

sodium bisulfite solution, and diluted with ethyl acetate. The organic phase was washed with water, dried with sodium sulfate and concentrated *in vacuo*. Purification of the crude product mixture by flash chromatography (20% ethyl acetate in hexane) yielded 22.7 mg (16%) of Example 647: LC/MS (m/z 629, $(M+H)^+$).

5

EXAMPLES 647 TO 648

In a manner similar to Example 646, Examples 647 to 649 were prepared.

Example	Chiral Compounds	Structure	MS: (M+H = MW +1)
647			472.35
648	Chiral (S)		472.35
649	Chiral (R)		472.35